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1. Zusammenfassung 
Protein-Protein-Interaktionen spielen eine Schlüsselfunktion in fast allen biologischen 
Prozessen. Dennoch sind konventionelle Methoden, um diese Interaktionen nachzuweisen, 
wie beispielsweise das Hefe-Zwei-Hybrid System, üblicherweise sehr aufwendig und 
kompliziert. Häufig werden Protein-Protein-Interaktionen auch mithilfe des Förster Resonanz 
Energietransfers (FRET) vor allem bei der Konfokalmikoskopie gemessen. Diese Methode 
produziert allerdings riesige Datenmengen und verlangt dazu viel Fachwissen. 
Um diese Einschränkungen zu überwinden, wurde hier eine Methode entwickelt, mit der 
sich Protein-Protein-Interaktionen automatisch und auf Einzelzellbasis mit Hilfe der 
Durchflusszytometrie am MACSQuant Durchflusszytometer nachweisen lassen, da hier die 
FRET-Effizienz automatisch berechnet wird. Änderungen im Status der Protein-Protein-
Interaktionen werden durch relative Änderungen in der Intensität der FRET Donor- und 
Akzeptorfluorochrome erfasst, wodurch sich der Wert der FRET-Effizienz ändert. So können 
Protein-Protein-Interaktionen sehr einfach auch auf hohen Zellzahlen in äußerst geringer 
Zeit und in Hochdurchsatzscreenings gemessen werden. 
In der vorliegenden Arbeit konnte gezeigt werden, dass die CD3 und CD4 Korezeptoren auf 
der T Zell-Oberfläche nach der Aktivierung mit SEB interagieren. Hier stieg die FRET-Effizienz 
nach der T Zell Aktivierung deutlich an. Weiterhin konnte auch die Clusterbildung des CD3 
Rezeptors durch das automatisierte Messen der FRET-Effizienz nachgewiesen werden. Auch 
wenn das FRET-Fluorochromenpaar gewechselt wurde, waren die Messergebnisse 
vergleichbar. Der Nachweis der T Zell Aktivierung gelang mit der FRET-Analyse sogar 
schneller als durch die Messung des Anstiegs an intrazellulären Kalziumionen als Standard-
Aktivierungsmarker. Daher wurde auch getestet, ob auf Blutproben von immundefizienten 
Patienten, die in der Clusterbildung ihres CD3-Rezeptors aus verschiedenen Gründen 
eingeschränkt waren, diesen Defekt nachgewiesen werden konnte. Tatsächlich konnte hier 
im Vergleich zu gesunden Spendern kein Anstieg in der FRET-Effizienz nach T-Zell Aktivierung 
gemessen werden. Aus diesem Grund könnte die automatisierte FRET-Analyse auch im 
klinischen Alltag zum Nachweis von speziellen Immundefekten verwendet werden. 
Mit Hilfe der CD3-Clustering FRET-Analyse konnte außerdem den Einfluss der Integrität der 
Lipid Rafts auf das Clustervermögen des CD3 Korezeptors nachgewiesen werden. Wurden 
Zusammenfassung 
 
2 
 
die Lipid Rafts mit Hilfe verschiedener Chemikalien modifiziert, nahm die FRET-Effizienz nach 
T Zell Aktivierung verglichen zu unbehandelten Zellen ab. 
Weiterhin konnten die automatisierte FRET Analyse auch genutzt werden, um 
Immun-Checkpoint-Inhibition auf T Zellen zu bestätigen. Dafür wurde mittels FRET die 
Interaktion der CD3 und PD-1 Rezeptoren nach einer längeren T Zell-Stimulation gemessen: 
hier stieg die FRET-Effizienz deutlich an. Dieser Anstieg konnte jedoch verhindert werden, 
indem blockierende Antikörper, die gegen die Liganden des PD-1-Rezeptors gerichtet sind, 
verwendet wurden. Diese Antikörper unterbinden die Kostimulation, die für die 
antigenpräsentierende Zelle essentiell ist, um sich der Erkennung des Immunsystems 
erfolgreich zu entziehen. Folglich ist die automatisierte FRET-Analyse auch eine 
leistungsstarke Methode, um im Hochdurchsatzverfahren nach pharmakologisch aktiven 
Wirkstoffen, die diese Checkpoint Inhibition unterbinden, zu screenen.  
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1. Summary 
 
Although protein-protein interactions play a major role in almost all biological functions, 
those interactions cannot easily be analysed, especially not on single cell level and with 
regard to dynamic changes in protein arrangement. Conventional investigation methods, like 
the yeast two-hybrid system are highly time consuming. Förster resonance energy transfer 
(FRET) is commonly used to identify protein-protein interactions via confocal microscopy. 
However, this requires expert knowledge and produces high amounts of data. 
In order to overcome those limitations, a program was developed that automatically 
measures and calculates the FRET efficiency on cell by cell basis on the MACSQuant flow 
cytometer. Changes in protein-protein interactions can be assessed via relative signal 
changes of the donor and acceptor fluorochromes, causing a change in FRET efficiency. This 
allows for the identification of protein-protein interactions on large cell numbers in a 
minimum of time, in high throughput screenings and is easy to use. 
In this study, it could shown that interaction of the CD3 and CD4 coreceptors can be 
measured on the T cell’s surface after activation via an increase in FRET efficiency. 
Furthermore, also the homoclustering of the CD3 coreceptor could be detected using the 
automatic FRET measurement. Even when the FRET fluorochrome pair was changed, the 
results were highly comparable. For this experiment, the increase in FRET efficiency was 
even faster than the increase in intracellular calcium that is used as the standard activation 
marker. For that reason, this automatic assay had been used to test blood samples of 
patients that are suffering from severe immunodeficiencies and are compromised for 
different reasons in their ability of CD3 clustering. Indeed, here no increase in FRET efficiency 
could be measured compared to healthy blood donors. Therefore, the automatic FRET 
program can easily be used in clinical settings for the determination of certain 
immunodeficiencies in patients. 
Moreover, using the CD3 homoclustering FRET essay, the impact on lipid raft integrity on the 
clustering of CD3 could be detected. If the lipid rafts were manipulated, the CD3 receptor 
could not cluster effectively after T cell stimulation, leading to a decreased FRET efficiency 
compared to untreated T cells. 
The automatic FRET assay could also be used to determine the checkpoint inhibition in T 
cells. For that purpose, the interaction of CD3 and the PD-1 receptor was measured after a 
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prolonged T cell stimulation leading to an increased FRET efficiency. That increase could be 
inhibited by applying blocking antibodies that are directed against the PD-1 ligands, 
prohibiting the co-stimulation that is essential for a successful immune escape. Therefore, 
this method is also a powerful tool allowing for high throughput screenings for 
pharmacologically active compounds. 
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2. Introduction 
 
2.1 FRET 
Usually in flow cytometry, the overall fluorescent signal of a single cell is measured. This 
provides information on the presence or expression level of a certain target molecule on the 
cell. However, no information can be derived on the special distribution of this molecule or 
its interactions with other molecules of interest. Still, protein-protein interactions play a 
major role in almost all biological functions. To overcome the limitation in spatial resolution, 
the Förster resonance energy transfer (FRET) between two fluorescent molecules can be 
determined on a flow cytometer. 
In 1948, Theodor Förster described a process in which a fluorescent donor molecule in an 
excited state transfers its energy via nonradiative dipole-dipole interactions to a neighboring 
acceptor molecule1. However, FRET requires an overlap of the emission spectra of the donor 
with the acceptor excitation spectra2. The efficiency of the energy transfer is strongly 
distance depended. The energy transfer (E) decreases with the power of six with an increase 
of distance between the donor and acceptor, as described by the Förster radius R:  
 
 
Equation 1: Förster radius 
 
Therefore, the energy transfer can usually not occur for distances larger than 10 nm2. As the 
range of 10 nm is the dimension in which protein-protein interactions normally occur, this 
makes FRET an important tool to measure protein-protein interactions. For that reason, 
FRET is also known as a ‘spectroscopic ruler’3 and already found many applications in 
microscopy and flow cytometry4,5.  
As a results of the energy transfer leads to a reduction of donor fluorescence intensity is 
reduced and therefore an increase in acceptor fluorescence emission can be measured when 
excited with the FRET donor wavelength6. 
There are still some major constraints in the application of the FRET system. Traditionally, 
FRET signals were measured via microscopy7. However, this produces high amounts of data 
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and requires expert knowledge for the subsequent data analysis. Furthermore, as a 
consequence of the spectral overlap between donor and acceptor, the spillover in the 
respective channels makes the measurement of a clear FRET signal more complex. For that 
reason, numerous controls have to be included in the experiment and complex calculations 
are required in order to exclude measurement artifacts. To enable the analysis of large cell 
numbers, a FRET analysis program had been previously developed. However, it only allows 
for a computer-based post-measurement analysis. 
Besides, in all FRET applications the size of fluorophores has to be considered, because steric 
effects of large and bulky fluorophores might inhibit a successful energy transfer. For that 
reason, not observing a FRET effect does not necessarily indicate for no molecular 
interactions to take place8. 
 
2.2 FRET Efficiency calculation 
FRET efficiency describes the rate of absorbed photons that are transferred non-radiatively 
from the donor molecule to the acceptor: 
 
 
 
Equation 2: FRET Efficiency 
 
Here, κET describes the rate of energy transfer, κf the radiative decay rate and κi the sum of 
other de-excitation rates4. If energy transfer occurs, the quantum yield of the donor will 
become smaller and thus donor fluorescence intensity will decrease. As this energy is 
transferred to the acceptor molecule, this leads to an increase in the amount of acceptor 
molecules in an excited state and therefore to an increase in acceptor fluorescence intensity. 
However, these differences can often not be clearly distinguished via optical evaluations in 
diagrams and should therefore be calculated as FRET efficiency. 
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Figure 1: Emission spectra in FRET. The donor intensity is decreased (red) in FRET double stainings in comparison to single 
stainings (light blue), whereas the acceptor intensity is increasing (blue) compared to single stainings (green). In addition, 
the signal in the FRET channel is increased by FRET (green), compared to non-FRET samples (pink). 
 
Here, we calculated the FRET efficiency according to published and established 
calculations4,9,10 on background corrected raw fluorescence intensities on cell-by-cell basis11. 
As the fluorescence spectra of donor and acceptor are overlapping, these signals cannot be 
separated by optical filters.  
To determine the contribution of donor and acceptor the in respective signals, each of the 
three measured intensities (I1, I2 and I3) will also have direct contributions from the donor 
and acceptor intensities (ID and IA, respectively) as well as the energy transferred intensity 
(ID*E): 
 
 
Equation 3: Measured intensities for donor, acceptor and FRET and the contributions from other intensities. 
Using these intensities, the spectral correction factors (S1, S2, S3 and S4) that account for the 
spectral contributions to each of the channel can be determined. The factors can be 
calculated on single-fluorophore labeled samples using the following equation: 
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 and  for donors, and 
 and  for acceptors. 
Equation 4: Spectral correction factors for FRET donors and acceptors. 
 
Furthermore, the alpha factor as a scaling factor for the relative detection efficiency has to 
be determined using single labeled samples. The alpha factor normalizes for the conversion 
of a donor fluorophore excitation that gets emitted by an acceptor fluorophore, and can be 
determined empirically using this formula: 
 
 
Equation 5: Scaling factor alpha 
 
Here, F is the fluorophore to antibody labeling ratio, b the average amount of bound antibody (it is 
assumed to be identical for donor only and acceptor only labeled samples) and ε is the extinction 
coefficient of the fluorophores excited at the maximum donor excitation wavelength. 
When A is substituted with A = E / ( 1 – E ), the equation set can be solved to: 
 
 
Equation 6: Equation for A 
 
Normally in biological systems the correction factors S3 and S4 are approaching 0, and also in our 
system we found that both factors were <0.01. For that reason, we could use a simplified equation 
derived from Equation 6: Equation for A to calculate the FRET efficiency: 
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Equation 7: Simplified equation for A 
 
The FRET efficiency is determined here as a pure sensitized emission signal (SE) that is normalized to 
the total donor signal as converted to the acceptor emission12: 
 
 
Equation 8: Equation for the FRET efficiency as sensitized emission signal 
 
2.3 The human immune system 
The human body is constantly exposed to microorganisms like bacteria, viruses, funguses or 
parasites that can potentially be disease-causing to the organism. The substances that the 
immune system is recognizing is referred to as antigens, as those substances were primarily 
discovered to stimulate the antibody generation. Antigens may not only consist of proteins 
or polysaccharides, but can also be comprised of metals, chemicals or even drugs.13  
Several mechanisms have evolved to protect the body very efficiently from most of the 
diseases14. Those mechanisms, called the immune response, can be further subdivided into 
two different approaches of defense.  
The first line of defense, the innate immunity, is a germline-encoded general but unspecific 
immune response. It is instantly available as soon as a pathogen is recognized via its specific 
pattern, but does not protect in a long-lasting manner. Here, the pathogens are destroyed 
by different immune cell types immediately before they can even infect the organism and 
cause a disease15. 
The adaptive immune response is highly specific against the pathogens16. It called adaptive 
because it is constantly developing during a human’s live during encountered infections. In 
the case of infection, it might take days until the specific immune response of the adaptive 
immune has developed. Yet, this immune response is highly efficient in eliminating the 
pathogen via very specific antigen receptors on the cell surface. The adaptive immune 
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response is also able to form an immunological memory against pathogens that it had once 
encountered, leading to a long-term immunity against that pathogen17. However, the 
adaptive immune response needs to be initiated via the innate immune system to form the 
immune response15. The major cell population that constitute to the adaptive immune 
system, the lymphocytes, can be further divided into B cells, that mediate a humoral 
immune response, and T cells that lead to a cellular immune response.  
 
2.4 T cells and T cell activation 
T lymphocytes make up a major part of the adaptive immunity and are characterized by the 
expression of the surface protein CD3. They are derived from the bone marrow but migrate 
into the thymus where they develop the T cell receptors (TCR) and are selected for their 
specificity to foreign antigens in the first step. These T cells are only able to recognize 
antigens that are presented on a major histocompatibility (MHC) complex as short peptide 
fragments18,19.  
There are two major T cell subsets: 
• The T helper cells express the surface protein CD4 and have a high affinity for the MHC 
Class II receptor. They induce the activation of other cells like cytotoxic T cells and lead to 
antibody class switching in B cell via the release of cytokines. 
• The cytotoxic T cells express the surface protein CD8 and are involved in the defence 
against viruses and tumours. They recognize virus infected or degenerated endogenous 
cells via their MHC Class I complex and induce their destruction. 
Likewise, the MHC receptor subtypes are expressed differentially20: The MHC class I receptor 
is normally found on almost all cell types and present peptides from fragments of non-self 
proteins from cytosolic proteins such as viruses but also tumor specific peptides21. The 
expression of the MHC class II receptor is restricted to antigen presenting cells like B cells, 
macrophages and dendritic cells. Therefore peptides are presented that are derived from 
phagocytosed extracellular proteins22. For both MHC types, the expression is tightly 
regulated via cytokine release like interferons from other immune cells. 
The initiation of adaptive immune responses takes places in lymphoid organs23. Here, during 
the naïve CD4 T cell activation, an immunological synapse (IS) is formed and the T helper cell 
receives two signals: first, the TCR/CD3 complex binds to the MHC II peptide complex24. This 
process also requires for the engagement of the CD4 or CD8 coreceptor. Here, the molecules 
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are approaching in close spatial proximity. This again triggers the phosphorylation of 
intracellular kinases to activate an intracellular pathway. The second signal provides the 
verification for the activation process. Here, the costimulatory molecule CD28 on the T cell 
surface binds to B7 molecules on the antigen presenting cell25,26.  
Briefly, the engagement of the TCR to a pMHC complex leads to a phosphorylation of ITAMs 
(immunoreceptor tyrosine-based activation motif), that are associated to the CD3 receptor. 
The ITAMs are phosphorylated via two different enzymes that belong to the Scr 
(sarcoma-associated kinase)-family: Fyn (fibroblast yes-related non-receptor kinase) and Lck 
(lymphocyte kinase), as they are recruited to the intracellular domain of the CD3 coreceptor 
during activation. The negatively charged phosphate groups at the ITAMs serve as binding 
partner for SH2 (src homology 2) domains for Zap-70 (ζ-associated protein of 70 kDa). After 
Zap-70 is recruited to the cell membrane, it becomes activated via Lck. There are several 
transmembrane adapter proteins that, once they are phosphorylated, recruit further 
cytosolic proteins like phospholipase Cγ (PLCγ), protein kinase C ϴ(PKCϴ) and Ras (rat 
sarcoma). 
PKCϴ hydrolyzes PIP2 (phosphatidylinositol-4,5 biphosphate) into IP3 (inositoltriphosphate) 
and DAG (diacylglycol), which causes an increase of intracellular free calcium ions. The ions 
interact with calcineurin and calmodulin. Calcineurin causes the dephosphorylation of the 
transcription factor NFAT (nuclear factor of activated T cells). This in turn causes NFAT to 
translocate into the nucleus. Furthermore, DAG binds the cytosolic serine/threonine kinase 
PKCϴ that induces the translocation of the transcription factor NF-κB (nuclear factor ‘kappa-
light-chain-enhancer’ of activated B-cells) into the nucleus. The GTPase Ras induces the MAP 
(mitogen-activated protein) kinase pathway, that activates the transcripton factor complex 
AP-1 (activator protein 1) to translocate into the nucleus and bind to the DNA. 
As a consequence of the T cell activation, several cytokines are released that regulate the 
differentiation of a T cell into a further subtypes of effector cells and their proliferation. The 
T Helper cell activation pathway is depicted in Figure 227. 
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Figure 2: Activation of T helper cells. The engagement of the TCR and its coreceptor CD28 induces several intracellular 
pathways, mainly via PKCϴ, Ras and PLCγ. Therefore, pro-inflammatory genes like IL-2 are transcribed and the T cell 
becomes activated. From: Pollizzi and Powell, 201427. 
 
2.4.1 Structural rearrangements in the IS 
During T cell activation, several structural rearrangements take place on the cell surface. 
After the T cell had successfully recognized a MHC-peptide complex, it is induced to stop 
migrating and forms a stable cell contact with the APC. For this, the TCR and its CD4 
coreceptor both have to bind to the MHC-peptide to induce intracellular activation 
signaling28. Here, the T cell builds up a pronounced polarization of to the antigen presenting 
cell as the microtubule organization center (MTOC) is reoriented to the immunological 
synapse (IS). This polarization process recruits all the cell surface receptors that are required 
for the immune response to the site of cell to cell contact29. 
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Finally, the T cell builds a distinct structure at the interface to the antigen presenting cell in 
which the key molecules that play a major role in immune response regulation are organized 
in very distinct areas30. Theis supra-molecular activation complex (SMAC) is subdivided into 
three different areas: in the central region of the SMAC (cSMAC) all the receptors that are 
required for a successful antigen recognition like the TCR and the CD3 coreceptor and their 
corresponding signaling kinases are gathered31. The receptors that are required for cell 
adhesion like LFA1 and ICAM1 are located in the peripheral SMAC surrounding the cSMAC. 
Also accessory receptors like the CD4 coreceptor are rapidly transferred to periphery32 after 
the initial contact to the APC has taken place. Molecules that are large and bulky and might 
have an inhibitory effect on synapse formation and T cell activation are located in the most 
distal region of the SMAC. Here molecules such as CD43, CD44 and CD45 can be found. 
 
 
Figure 3: Structural rearrangements in the immunological synapse. Central: activation receptors, middle: adhesion 
molecules, periphery: large and inhibitory molecules. Inhibitory molecules are depicted in grey, whereas activating 
receptors are shown in blue. From: Huppa and Davis, 200330.  
 
However, it was also shown that both the CD4 coreceptor and CD3 are internalized after 
strong activation signals via endocytosis. Whereas CD3 is recycled to the cell surface again, 
CD4 becomes degraded33. 
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2.4.2 CD3 clustering immunodeficiencies 
Some people fail to successfully create the immunological synapse and therefore are 
suffering from severe human primary immunodeficiencies, as the T cell cannot be activated 
and react properly to pathogen invasion into the body34. Several of the immunodeficiencies 
that are described to impair the clustering of the CD3 coreceptor on T cells.  
For example, patients that are deficient in the guanine nucleotide exchange factor dedicator 
of cytokinesis8 (DOCK8) are impaired in cytoskeletal rearrangements that are required for 
the formation of the IS. The DOCK8 deficiency is therefore characterized by a reduction of 
peripheral CD4 and CD8 T cells and impaired T cell proliferation and activation after CD3 
receptor stimulation with anti-CD335. For that reason, patients are often affected by for 
example sinopulmonary and viral infections, hyper-IgE as well as cutaneous cancer and 
lymphoma36,37.  
Patients that are suffering from the Wiscott-Aldrich syndrome (WAS) have a gene mutation 
in WAS that causes a lack of functional Wiscott-Aldrich syndrome protein (WASP). However, 
WASP is essential for the activation of actin polymerization and therefore in those patients 
also the cytoskeletal rearrangements that are required to induce the formation of the IS 
after T cell activation is impaired38. The syndrome is characterized by abnormal functions of 
most leukocytes. Patients often develop eczema and are in general very susceptible to 
infections as well as autoimmune disorders and lymphoma39. 
The MHC class II deficiency (bare lymphocyte syndrome) is a rare disease that is caused by 
mutations in the MHC class II, causing the respective molecule to be not expressed. For that 
reason, antigen presentation is impaired and the CD4 T cells cannot be activated 
specifically40. Therefore, the patient’s immune system is highly compromised. Those patients 
are extremely susceptible to all kinds of viral, bacterial and fungal infections41. 
 
2.4.3 Lipid rafts 
The lipid raft concept postulates that membrane trafficking and signaling can be regulated 
via nanoscale sphingolipid-cholesterol-protein assemblies within the cell membrane42. Those 
small structures are dynamically organized to merge to more stable larger raft structures to 
provide for specific molecular (lipid-lipid, lipid-protein and protein-protein) interactions after 
activation43.  
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Lipid raft clusters in the TCR domains of activated T cells show a selective enrichment of 
cholesterol44. Therefore the lipid rafts are recruited via radial movements that are regulated 
by actin filaments to the site of APC contact to form the cSMAC in the IS after TCR 
engagement. Here, inactive and dephosphorylated TCRs and their associated molecules 
(LAT, LCK and CD2) are replaced by active ones from the lipid rafts45,46 and the binding 
affinity and kinetics between the TCR and the pMHC is greatly enhanced47.  
 
 
 
Figure 4: TCR and CD3 receptor organization on lipid rafts in the immunological synapse. The CD3 and TCR are organized 
in lipid rafts on the cell surface. After T cell activation, those rafts are relocated via actin filament rearrangements to the IS. 
From: Simons & Gerl, 201048. 
 
There are several mechanisms that can be used to a modify the integrity of the lipid rafts. 
Hydroxypropyl Beta Cyclodextrin (bCD) is known to deplete the cholesterol molecules from 
lipid rafts due to its hydrophobic cavities as the chemical traps the molecules inside49. It had 
been described in literature that bCD treatment of T lymphocytes reduces the efficient 
engagement of the TCR to pMHC50.  
bCD in a lower concentration can also be applied to resolve cholesterol in order to introduce 
additional cholesterol into the cell membrane as this leads to an enrichment of cholesterol in 
the lipid raft49. 
The antifungal agent nystatin can be used to disrupt lipid rafts as it sequestrates the 
cholesterol molecules49. 
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2.4.4 Staphylococcal enterotoxin B 
Instead of specific antigens, also superantigens can be used to stimulate T cells 
unspecifically. 
Staphylococcal enterotoxins belong to the family of superantigens, which are secreted by 
various strains of Staphylococcus aureus51. In humans, those toxins lead to the biological 
effects of food poisoning and can also have lethal effects in high doses, but furthermore 
those toxins do also cause strong immune responses which are magnitudes greater than 
immune responses caused by conventional antigens52. Similar to the conventional antigens, 
superantigens are presented to a TCR on the MHC class II receptor of the antigen presenting 
cell, but in contrary to the normal antigen activation, superantigens strongly crossling the 
TCR with the MHC receptor. This leads to an unspecific stimulation of the T cell. Although 
downstream signaling differs from normal antigen stimulation in some activation 
pathways53, a non-MHC restricted T cell activation is triggered and leads to structural 
rearrangements on the cell surface as well as T cell proliferation and cytokine production. 
Additionally, the T cell activation via superantigens induces a strong internalization of the T 
cell receptor. As the Staphylococcal enterotoxin superantigen only interacts with the Vβ 
chain of the TCR, it can activate the large proportion of T cell subsets bearing the 
appropriate Vβ region regardless of the TCR chain specificities54. In general, approximately 
30% of the T cell population are activated by SEB55. 
 
2.5 Immune checkpoint inhibition 
Some tumor cells developed certain mechanisms to escape from the immune response of 
the T cells and therefore impair the T cells’ immune functionality56. This effect is the 
so-called immune checkpoint inhibition, an effect that normally terminates the immune 
response after antigen activation. Here, the inhibitory receptor programmed cell death 1 
(PD-1, also called CD279), a member of the CD28 superfamily57, can be inducibly expressed 
on T lymphocytes, but also on B cells and myeloid cells58. The receptor consists of a IgV-like 
domain with a transmembrane domain and a cytoplasmic tail that contains tyrosine-based 
signaling motifs58 which negatively regulate T cell signaling59. It inhibits the phosphorylation 
of Zap70 and protein kinase C ϴ at the CD3 coreceptor60 as well as the induction of 
phosphatidylinositol-3 kinase activity and the downstream activation of Akt61 from the CD28 
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receptor. This leads to a reduced stability of synapse formation to the APC. During acute 
infections, the PD-1 is downregulated for the duration of the antigen exposure62. 
The signaling of the PD-1 receptor can be induced via its engagement to the respective 
ligands PD-L1 (B7-H1) and PD-L2 (B7-DC). While the expression of PD-L2 is restricted to 
professional APCs63, PD-L1 can be found on various tissues and immune cells.  
The expression of PD-L1 is often upregulated on cancer cells and can be induced by 
proinflammatory cytokines such as type 1 and 2 interferons, TNF-α and IL-2, IL-7 and IL-1564.  
When T cells are constantly exposed to chronically infected cells, they will eventually 
become non-functional exhausted T cells65. However, a PD-1 deficiency leads to 
autoimmune-related diseases with a later onset in life66 as for example systemic lupus 
erythematosus. This indicates for PD-1 playing a major role in the regulation and the 
maintenance of self-tolerance of the immune response.  
 
2.5.1 PD-1 and CD3 colocalization 
Based on the suggestion that T cell activation is initiated via small TCR microclusters and its 
respective coreceptors and proximal signaling molecules67, it was discovered that those 
clusters also play a role in the regulation of the immune response. PD-1 that is expressed on 
effector T cells is translocated to those TCR microclusters before it accumulates in the 
cSMAC after engagement to its ligands68. In those microclusters the PD-1 receptor is located 
in close spatial proximity to the receptors to induce a SHP2-mediated supression of Zap70 
(see figure 5). Not only the clustering of PD-1, but also the colocalization with the TCR/CD3 
complex seem to be required to successfully inhibit T cell activation via PD-1 signaling. 
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Figure 5: PD-1 colocalizes with the CD3 coreceptor in a ligand-dependent manner. Cells that were transfected with PD-1-
EGFP (green) and stained with DyLight 649–labeled H57 Fab (red). Analysis was performed on a planar bilayer and 
realtime confocal microscopy at 2 minutes or 20 minutes after contact either in the presence or absence of PD-L1. The 
histograms show the fold fluorescence intensities of  theTCR (red) and PD-1 (green). Bars = 5 µm. From: Yokosuka et al., 
201268. 
 
Therefore the regulation of the T cell activation and immune response seems to be 
controlled via the spatiotemporal distribution of the TCR/CD3 complex together with the 
PD-1 receptor. 
For that reason the regulation of the PD-1/TCR microclusters might represent a novel and 
promising target to block tumor checkpoint inhibition. 
 
2.5.1 Pharmaceutical use immune checkpoint inhibition modulators 
In order to restore the immune functionality of exhausted T cells, the PD-1/ PD-1 ligand 
interaction can be blocked for example by using monoclonal antibodies69. This restores the 
functionality of the T cells in vivo and can be used for the treatment of certain cancer 
types70. 
In the last years, in the therapeutic area of immune checkpoint inhibition a monoclonal 
antibody (ipilimumab)71 directed against the immune checkpoint inhibitor receptor cytotoxic 
T-lymphocyte-associated Protein 4 (CTLA-4) had been tested for the treatment of metastatic 
melanoma. Although the therapeutic effect could be proven, patients suffered from severe 
and antigen unspecific side effects72.  
In contrary, the mode of action of PD-1 checkpoint inhibition is in most cases restricted to 
the periphery during chronic infection, causing inflammation, or against cancer. For that 
reason, autoimmune-mediated side effects will be less dramatic73. Mostly, but not 
exclusively, the expression level of PD-L1 on tumor tissue can be used as a prognostic factor 
and biomarker for an antibody immune therapy74. Patients who are tested to be positive for 
this marker do mostly show a better therapeutic outcome to antibody treatment. However, 
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It is still debatable to use solely rely on the PD-L1 expression in patients material for 
different reasons: first, the development of adequate antibodies that will still bind 
successfully to its epitope in fixed and paraffin embedded tissue samples is highly difficult 
and therefore often unspecific. Furthermore, PD-L1 may not only be expressed on the tumor 
cells only, but also on the immune cells that infiltrate the tumor microenvironment75-77. For 
that reason, several patients who were tested to be PD-L1 negative nevertheless showed a 
good response to anti-PD1 directed immunotherapy78. 
Two of those PD-1 checkpoint inhibition modulators had already been tested in clinical trials 
and are also FDA-approved for several different cancer subtypes: nivolumab (trade name: 
Opdivo®) and pembrolizumab (Keytruda®) were proven to be efficient in restoring the 
antitumor immune response against several advanced cancer types, including lung cancer, 
colorectal cancer and renal cell cancer79,80. Sill, also here several off-target effects such as 
autoimmune disorders like pneumonitis, vitiligo, colitis, hepatitis, hypophysitis and 
thyroiditis could be observed in patients81. Several more therapeutics targeting the 
PD-1/PD-L1 interaction are currently in the developmental pipeline of different 
pharmaceutical companies as there is still a high unmet need for the identification of new 
inhibitors and to clarify the detailed mechanism of work of pharmaceutically active 
compounds82. 
 
2.6 Flow cytometry 
In order to detect the presence of a certain target molecule on a cell, cells are commonly 
analyzed via flow cytometry83. 
Here, cells in a suspension are singularised and hydrodynamically focussed by a sheath fluid 
before beams of laser light are directed at the cell in an optical cuvette84. Usually, multiple 
lasers of different wavelength excite the fluorochromes which are labelling certain target 
molecules on the cells. The fluorescent light that is then emitted by the fluorescent dyes falls 
through filters which block any light except for the aimed wavelengths and is directed via 
mirrors to the respective photomultiplier tubes (PMTs). Those PMTs amplify and digitalize 
the fluorescent signal, thereby providing multiparametric information on the deflection of 
light in the form of the forward scatter signal (FSC, corresponding to the cell size) and the 
side scatter signal (SSC, corresponding to the granularity of the cell) and the also on 
fluorescence intensities that had been detected from a single cell. 
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Data analysis is normally performed via gating based on the fluorescence intensity of a cell 
population85. Here all events in a specific region in a diagram are selected for further 
analysis. Gates can be set in a hierarchic manner. This allows for a stepwise selection of 
specific subpopulations that are of special interest. 
 
2.6.1 Fluorochromes 
Fluorochromes absorb light of a certain wavelength, as the energy of the laser light puts the 
electrons of the fluorochrome from their ground state S0 into an elevated energy state S1 to 
S2. The time the fluorophore remains in the elevated level is referred to as the fluorescence 
lifetime. When an electron falls back into its basic energy state with the lowest vibrational 
energy level, photons are emitted again during the relaxation process. As a part of the 
energy is lost in the form of other de-excitation ways, the emitted light has a shorter 
wavelength compared to the excitation wavelength86.  
  
Figure 6: Energy states of an electron. The Jablonski diagram shows that in this example, the energy of the ultraviolet 
photon (blue) raises the energy level of a molecule from the ground state S0 to an ecxitet energy level S1 to S2. When the 
photon drops from the excited state to the gound state level, energy is lost in the form of fluorescent light (green). The time 
between those states is referred to as fluorescence lifetime. From: Lleres et al., 200786. 
  
The difference of wavelength between excitation maximum and emission maximum is 
referred to as stroke shift. However, fluorochromes do not only emit light of a certain 
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wavelength but a broad spectrum that is normally distributed around the emission 
maximum wavelength87. 
 
2.6.2 Express mode and post processing parser 
Data acquisition and the evaluation of samples that are measured on the MACSQuant flow 
cytometer are controlled and provided within MACSQuantify Software. The measured data 
are stored in a digital format, that allows post measurement compensation and individual 
analysis by gating and cell counts. Analysis templates created within the software can be 
saved to facilitate future evaluations. 
For an easy and fast analysis of complex cell analyses, as it might be required for multipanel 
analyses or for enrichment and enumeration kits, the MACSQuantify software offers several 
Express Modes. These Express Modes simplify the analysis via predefined experiment 
settings, including both acquisition templates for cell measurement and also the analysis 
templates for the evaluation. The analysis templates apply an automatic gating adapted to 
each individual sample to identify the cells of interest. 
The sample grouping function allows the user to save more than one sample in one single 
data file. This might be necessary if volumes larger than 450 µl have to be measured. It is 
also helpful when the same gates shall be applied to more than one sample. This has the 
advantage that control stainings can be included or that certain values can be offset against 
each other. 
 
2.7 Objectives of the study  
In the study presented here, an automated FRET-based program for the detection of 
protein-protein interactions was to be developed for a commercially available flow 
cytometer (MACSQuant). This program will identify each population of interest that will be 
required to determine the FRET efficiency by using defined gating algorithms. Based on 
relative changes in donor and acceptor fluorochromes intensity, the FRET efficiency can then 
be calculated by this program, therefore providing information on the increase or decrease 
of the proximity between two molecules of interest. 
Using this method, a higher spatial resolution compared to conventional methods like 
confocal microscopy will be achieved. The analyses can be performed within a minimum of 
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time. This will allow for high-throughput screening, nevertheless without producing vast 
amounts of data or requiring expert knowledge for data analysis due to its automation.  
The program shall be used to measure the clustering of surface receptors that is induced by 
T cell stimulation and also to unravel dynamic changes that take place both on the cell 
surface and on intracellular level, especially with regard to the spatial regulation of the CD3 
and CD4 coreceptors. 
Furthermore, we will use this assay to identify active checkpoint inhibition on T cells by 
measuring the clustering of PD-1 and CD3 via FRET after a prolonged T cell activation. 
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3. Material 
 
3.1 Cells 
Buffy coat     University Hospital of Dortmund 
MDA-MB-231     ATCC 
HuT-78     ATCC 
Whole blood     Intern blood donation pool 
 
    
3.2 Instruments 
Centrifuge     Biofuge pico, Heraeus 
      4 KR, Heraeus 
Confocal Laser Scanning Microscope Zeiss LSM710 
MACSQuant Analyzer  10   Miltenyi Biotec GmbH 
MACSQuant VYB    Miltenyi Biotec GmbH 
MACSQuant-X     Miltenyi Biotec GmbH 
Sysmex KX-21 Hematology Analyzer  Sysmex GmbH 
Photometer     Ultraspec 3300 pro, GE Healthcare 
Vortex      Vortex genie 2, Scientific Industries 
Incubator (HERA Cell 240i)   Thermo Fisher Scientific Inc. 
 
 
 
3.3 Reagents 
96-well imaging chamber   Zell-Kontakt 
CliniMACS buffer    Miltenyi Biotec 
Hematology Analyzer    Sysmex KX21N, Sysmex Corporation 
Human Sera Type AB    BioWittaker 
PenStrep     Lonza 
MACS Bleach Solution   1% Active Cl- 
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MACSQuant Calibration Beads  Miltenyi Biotec 
MACSQuant Running Buffer   Miltenyi Biotec 
MACSQuant Storage Solution  Miltenyi Biotec    
MACSQuant Washing Solution  Miltenyi Biotec  
Pancoll     PAN Biotech 
Paraformaldehyde 3.75%   Sigma Aldrich 
PEB      1 x PBS, 2mM EDTA, 0,5% BSA  
Phorbol 12-Myristate 13-Acetate  eBioscience 
Red Blood Cell Lysis Solution     Miltenyi Biotec 
RPMI 1640 cell culture medium  Miltenyi Biotec  
Staphylococcal enterotoxin B  Sigma Aldrich 
TransAct reagent    Miltenyi Biotec 
DMEM cell culture medium   Miltenyi Biotec 
Fetal Calf Serum    Biochrom AG 
Trypsin-EDTA     Thermo Fisher Scientific Inc.   
L-Glutamine     Lonza 
Blood Dendritic Cell Isolation Kit II, human Miltenyi Biotec  
Pan T Cell Isolation Kit, human  Miltenyi Biotec 
eFluor 514 Calcium Dye   eBioscience 
MACS GMP TransAct CD3/CD28 kit  Miltenyi Biotec 
Alexa Fluor 488 NHS Ester   Live Technologies 
Alexa Fluor 555 NHS Ester   Live Technologies 
Prionex     Pentapharm 
MACSPlex Cytokine 12 Kit   Miltenyi Biotec 
Trappasol     Cyclod. Techn. Dev. Inc 
Cholesterol     Sigma 
Nystatin     Sigma 
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3.4 Antibodies and antibody conjugates 
CD3-FITC, human    Clone BW264/56, Miltenyi Biotec 
CD3-VioBlue, human    Clone BW264/56, Miltenyi Biotec 
CD3-VioBlue, human    Clone BW264/56, self-conjugated 
CD3-APC, human    Clone BW264/56, Miltenyi Biotec 
CD3-Alexa Fluor 488, human   Clone BW264/56, self- conjugated 
CD3-Alexa Fluor 555, human   Clone BW264/56, self-conjugated 
CD4-VioBlue, human    Clone VIT4, Miltenyi Biotec 
CD4-APC, human    Clone VIT4, Miltenyi Biotec 
PD-1-sFITC, human    Miltenyi Biotec 
Anti CD3, human pure   Clone BW264/56, Miltenyi Biotec 
Mouse anti-SEB antibody pure  Clone B87.10, ImmuQuest 
Anti PD-L1 pure    Abcam 
Anti PD-L2 pure    Abcam 
APC anti-human CD274 (B7-H1, PD-L1)  BioLegend 
Anti-PD-L2 FITC    Miltenyi Biotec 
CD45-APC     Miltenyi Biotec 
TCR      Miltenyi Biotec 
 
3.5 Consumables, others 
Cryo tubes     Thermo Fisher Scientific Inc. 
Immersion oil, Immersol 518   Zeiss 
PD 5, 10 columns    GE Healthcare 
Pipette tips     Starlab 
MACS Separator     Miltenyi Biotec 
MACS separation columns   Miltenyi Biotec 
Flat bottom cell culture plates     Falcon (BD Biosciences) 
Round bottom cell culture plates  Falcon (BD Biosciences) 
75cm2 cell culture flasks   Falcon (BD Biosciences) 
Cell Strainer 70 μm    Miltenyi Biotec 
Serological pipettes    Sarstedt 
Microcentrifuge tubes   Starlab 
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3.6 Statistical Analysis 
For the experiments in this thesis, biological replicates were performed for the same 
experiments but from blood samples drawn on separate days. Usually the number biological 
replicates was n=3, with the exception of the immunodeficient patients. Due to restricted 
availably, the number of replicates was only n=2. For the determination of significance 
between untreated and treated samples, the paired two-tailed Student’s T test was used and 
for the comparison of multiple treatments, a one-way ANOVA test was followed by 
Holm-Sidak’s multiple comparison test. Values with p<0.05 were considered to be 
significant. Error values for the biological replicates were determined as standard error of 
mean (s.e.m.).  
 
3.7 Software 
The statistical analyses were performed using GraphPad Prism version 6.02 and 7.00 for 
Windows. For all data and text editing, the software program Microsoft Word 365 Pro Plus 
(Microsoft) had been used. Python scripts were developed and edited using Spyder 3.5.2.5 
(Spyder Development Team). MACSQuant data analysis was performed using either 
MACSQuantfify Analysis software Versions 2.6 to 2.10 (Miltenyi Biotec GmbH) or a 
respective debug version for programming purposes. Confocal images were edited and 
analyzed using the ZEN2012 software (Zeiss). Graphical illustrations were designed using 
Adobe Illustrator CS3 13.0 (Adobe Systems). Furthermore, the EndNote X7 software 
(Thomson Reuters) was used for the citation of references within this thesis. 
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4. Methods 
4.1 Cell isolation and cultivation 
For the FRET experiments, primary cells from intern healthy blood donations from Miltenyi 
Biotec staff with given consent or from buffy coats from the University Hospital Dortmund 
had been isolated. For the measurements of immunodeficiencies, frozen PBMC samples 
from immunodeficient patients or the corresponding healthy control samples were obtained 
from the Center for Chronic Immunodeficiency Freiburg. The MDA-MB-231 cell line was 
obtained ATCC and stored intern cell stocks.  
All cell culture work was carried out in tissue culture hoods using sterile and pyrogenfree 
reagents and consumables. Cells were always grown as monolayers in cell culture dishes or 
in cell culture flasks. 
 
4.1.1 PBMC isolation 
Peripheral blood mononuclear cells were isolated from buffy coat or whole blood on the day 
of blood draw. Three falcon tubes were filled with 15 ml Pancoll, and 25 ml of buffy coat that 
had been mixed with 10 ml CliniMACS buffer was carefully overcoated. For whole blood, 30 
ml whole blood was diluted with 5 ml CliniMACS buffer before overcoating the Pancoll layer. 
The tubes were centrifuged for 35 minutes at 445 g with acceleration and break at the 
lowest level. Plasma was carefully removed and discarded. The lymphocytes on top the 
Pancoll layer were split into two fresh falcon tubes, filled up with CliniMACS buffer to 50 ml 
and centrifuged for 15 minutes at 300 g. Supernatant was removed, the cells were pooled 
into a fresh falcon tube and resuspended in 50 ml CliniMACS buffer. The PBMC were washed 
in RMPI supplemented with 2 mM L-glutamine and 0.05% (vol/vol) human AB-serum for 10 
minutes at 200 g and resuspended in 10 ml RPMI with supplements buffer. The cell number 
was determined on the Sysmex hematology analyzer. For the CD3-CD4 and CD3 clustering 
FRET experiments, the cells were plated in a 24-well plate with 1x107 cells per well in 2 ml 
medium for 48-60 hours at 37°C and 5% CO2. For PD-1 blocking experiments, the PBMCs 
were plated with 5x105 cells per well in a 24-well plate in RPMI with supplements for 3 days.  
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4.1.2 T cell isolation 
Untouched T cells were isolated from PBMCs using the Pan T cell Isolation kit according to 
the user manual instructions. For comparison, T cells were also isolated using the Blood 
Dendritic Cell Isolation Kit II with the respective change that both kit reagents were added at 
once to the PBMCs in order to achieve a dendritic cell depletion and therefore a T cell 
isolation. All other steps were carried out according to the user manual. 
For the PD-1 CD3 FRET experiments, either 1x106 T cells were plated in 1 ml RMPI 
supplemented with 2 mM L-glutamine and 0.05% (vol/vol) human AB-serum on a 24-well 
plate. For the downscale version for screening purposes 5x105 cells per well in in 50 µl RPMI 
with supplements a 384-well plate (downscale version) were cultured or co-cultured if 
indicated with MDA-MB-231 cells for 3 days at 37°C and 5% CO2 in humidified atmosphere.   
 
4.1.3 Freezing and thawing of cells 
For the freezing of cells, the cells were resuspended in 1 ml of the respective cell medium 
supplemented with 20% FCS and 10% DMSO and frozen at -80°C before the cells were 
transferred into liquid nitrogen tanks. 
Cells were thawed through incubation at 37°C in a water bath until the sample was almost 
thawed. Then the cells were quickly transferred into 12 ml of the respective cell medium in a 
15 ml centrifuge tube and washed for 10 min at 300g. The supernatant was discarded and 
the cells were washed a second time with 12 ml medium. Afterwards the cells were 
transferred into cell culture plates or flasks and cultured under the required conditions. 
 
4.1.4 MDA-MB-231 cultivation 
The human breast cancer cell line MDA-MB-231 was cultured in 10 ml DMEM supplemented 
with 10% FCS (vol/vol) and 1% PenStrep (vol/vol, 10,000 U/ml) at 37°C with 5% CO2 in a T-75 
cell culture flask in a humidified atmosphere. Cells were passaged in a ratio of 3:10 twice a 
week. For this, the cells were rinsed with CliniMACS buffer and incubated with 3 ml trypsin 
for approximately 5 minutes at 37°C. After the cells had detached from the flask, the cells 
were washed in 50 ml DMEM with supplements for 5 minutes at 300g, the supernatant was 
discarded and the cells were resuspended in 10 ml medium. 3 ml of cell solution was 
transferred into a fresh cell culture flask filled with 7 ml cell medium. 
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For the PD-1 CD3 FRET assay, 2.25 x 104 cells were plated in a 384-well plate or 5x105 cells 
were plated in a 24-well plate in DMEM with supplements and co-cultured with T cells as 
described in 4.1.2 T cell isolation. 
 
4.2 T cell activation and SEB blocking 
T cells were activated using either staphylococcal enterotoxin B (SEB) superantigen or the 
MACS GMP TransAct CD3/CD28 kit as described hereinafter.  
 
4.2.1 Activation protocol for T cells with SEB 
For the CD3-CD4 FRET experiments, 1x106 PBMCs were incubated with 2 µg SEB for 2 
minutes at 37°C if not stated differently. Here, a the high SEB concentration was used to 
achieve a full saturation for the short incubation time. For SEB blocking experiments, 0.5 µg 
of the mouse anti-SEB antibody (clone B87.10)88 was added to the cells. To achieve a molar 
antibody surplus of approximately 10x, here the SEB concentration was lowered to 0.2 µg 
accordingly. The blocking antibody was either pre-incubated with the SEB for 3h at 4°C or 
added to the cells in parallel with the SEB. For the PD-1 CD3 FRET experiments, the T cells 
were stimulated with 2 µg SEB for 3 days for the standard protocol. In the downscale 
version, the T cells were stimulated with 0.2 µg SEB for 3 days. 
 
4.2.2 Activation protocol for PBMC with TransAct Kit 
In order to activate T cells using the MACS GMP TransAct CD3/CD28 kit, 1x106 PBMCs were 
incubated with 500 ng of each the CD3-specific and the CD28-specific reagent for 2 minutes 
at 37°C. 
 
4.2.3 Cytokine secretion assay 
To validate the activation of the T cells, the cytokine secretion was determined after SEB 
stimulation. For this, 1x105 PBMCs were stimulated with 1 µg SEB in 200 µl RPMI medium 
with supplements over night at 37°C and 5% CO2. In this experiment, the SEB concentration 
was reduced compared to the standard T cell stimulation protocol because of the increased 
incubation time. The secreted cytokines were stained and measured using the MACSPlex 
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Cytokine 12 Kit according to the user instructions and the results were evaluated via the 
respective MACSPlex Cytokine 12 Express Mode program. 
 
4.2.4 Calcium influx measurements 
The intracellular, cytoplasmatic calcium influx into the activated cell was measured using the 
eFluor514 calcium indicator dye. This dye is suitable for calcium measurements on flow 
cytometers that are not equipped with an UV laser89. 1x107 PBMCs were stained with 5 µM 
eFluor514 in 1 ml RPMI with supplements for 30 min at 37°C. Afterwards, the cells were 
washed twice with the medium, resuspended in medium and kept at 37°C until stimulation. 
 
4.3 Fluorochrome conjugation 
The CD3ε-chain specific antibody (clone BW264/56) was labeled with different fluorescent 
molecules for a later FRET analysis. For this purpose, the VioBlue dye was added in a ratio of 
10 molecules per antibody molecules, Alexa Fluor 488  in  a ratio of 7.5:1 and Alexa Fluor 555 
in a ratio of 7.5:1. The anti-CD3 antibody was incubated on a shaker with the respective dye 
for 1.5 h in 0.1 M NaCO3 at room temperature under light protective conditions. In the 
meantime, a Sephadex gel column was equilibrated three times with phosphate-EDTA-azide 
buffer. The unconjugated dye was removed from the antibody conjugates via the 
fractionation on the gel column. The antibody conjugates were eluted using phosphate-
EDTA-azide buffer and were stored in a concentration of 100 µg/ml with the addition of 0.1% 
Prionex as stabilizer. We determined the labeling ratios of fluorochrome to antibody ratios 
photometrically: The VioBlue conjugate had a labeling ratio of 4.18, the Alexa Fluor 488 
conjugate a ratio of 2.95 and the Alexa Fluor 555 conjugate a ratio of 6.12. The antibody 
conjugates were titrated on PBMCs until they reached a saturation point. The CD3-VioBlue 
conjugate was furthermore cross-titrated with the CD3-FITC conjugate for the CD3 clustering 
FRET experiments in order to achieve a 50% reduction in fluorescence for the double labeled 
sample. 
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4.4 Staining protocols 
For all the cell stainings in which Miltenyi Biotec antibody conjugates or  BioLegend 
conjugates were used the cells were stained according to the instructions and 
concentrations indicated in user manual if not stated differently. 
For the CD3 CD4 FRET assay, 1x106 PBMCs were stained with a FITC conjugated anti-CD4 
antibody and a CD3-specific VioBlue antibody conjugate (Miltenyi sales LOT). For the CD3 
homoclustering assay 1x106 PBMCs were stained either with 5 µl of the self-conjugated anti-
CD3 VioBlue conjugate and 10 µl of the Miltenyi Biotec sales LOT anti CD4 FITC conjugate, or 
with 19 µl anti-CD3 Alexa Fluor 555 conjugate and 2 µl anti-CD3 Alexa Fluor 555 conjugate. 
The cells were stained at room temperature for 10 minutes in medium, then washed with 
medium for 5 minutes at 300g. The cells were resuspendend in 200 µl medium and kept at 
37°C until T cell activation. In case the Alexa Fluor FRET pair had been used, the cells were 
first stained as described above, stimulated with SEB as described in 2.4.4 Staphylococcal 
enterotoxin Band immediately fixed with 2.25% (vol/vol) paraformaldehyde at room 
temperature for 20 minutes. 
If the lipid rafts were disrupted during the experiments, the cells were either stained with 
the FRET pair antibody conjugates as described above before SEB stimulation or following 
the SEB stimulation for the given time points. 
For the CD3 PD-1 FRET experiments, 1x105 T cells were stained in 200 µl medium for 3 days 
after SEB stimulation with 10 µl of each the anti CD3-VioBlue (Miltenyi sales LOT) and 
anti-PD1 sFITC antibody conjugates, either in 200 µl medium (normal approach) or in 50 µl 
medium for the 384-well plate downscale approach. The cells were incubated with the 
antibody conjugates for 10 minutes at 4°C, then washed for 5 minutes at 300g with PEB 
buffer and resuspended in PEB buffer for cell measurements at the MACSQuant. Also for the 
downscale version, 10 µl of each antibody conjugate was used as the whole well of cells was 
measured and stained and a complete saturation with the antibody fluorochrome conjugate 
was to be achieved. 
 
4.5 Lipid raft integrity manipulation 
To change the integrity of the lipid rafts, hydroxypropyl Beta Cyclodextrin (bCD), cholesterol 
and nystatin were incubated with the SEB stimulated PBMCs. 
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For the βCD, a 100 mM dilution was mixed by dissolving 2.74g bCD in 20 ml dH2O. The 
cholesterol was dissolved to a 104 nM solution with 0.02g cholesterol in 20 ml dH2O and the 
addition of 2.74g bCD, because otherwise cholesterol would not dissolve in water. Both 
dilutions were sterile filtered through a 0.2 strain and stored at 4°C.  
The PBMCs were stimulated with 2 µg SEB and incubated with each 20 µl (corresponding to 
10 mM) bCD or cholesterol or with 2 µl nystatin solution for the given time points at 37°C. 
 
4.6 Confocal laser scanning microscopy and sample preparation 
For the observation under the confocal laser scanning microscope, PBMCs were stained with 
the indicated dyes as described in 4.4 and stimulated with SEB as described in 4.2 T cell 
activation and SEB blocking. The cells were fixed with 2.25% (vol/vol) paraformaldehyde for 20 
minutes at room temperature, washed at 300g for 5 minutes and resuspended in 50 µl PEB. 
The cells were analyzed on the Zeiss LSM 710 confocal microscope. 
 
4.6.1 Colocalization analysis at the confocal microscope 
The overlap coefficient was determined for the CD3 receptor and the CD4 coreceptor as 
described in Fehler! Verweisquelle konnte nicht gefunden werden.. To compare the results 
obtained in the FRET experiments, the FRET values were normalized (FRETn) via linear fitting 
according to the following equation: 
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝐹𝐹𝑒𝑒𝑒𝑒 ∗ 3.6 + 18.48 
Further positive and negative controls were stained for the colocalization analysis. As 
positive controls, PBMCs were stained with CD3-FITC and CD45-APC as those receptors are 
known to colocalize as long as the T cell is not activated. Another positive control was the 
colocalization of CD3 and the TCR, as those receptors are described to form a complex. For a 
negative colocalization control, PBMCs were stained for CD3-FITC and CD45-APC after SEB 
stimulation for 1h at 37°C, because the stimulation causes the CD45 receptor to be 
segregated from the immunological synapse. All samples were fixed with 2.25% (vol/vol) 
paraformaldehyde.  
 
Methods 
 
30 
 
4.7 Flow cytometry 
For the flow cytometric analysis, all the samples that were stained with the Alexa Fluor dyes 
are analyzed on the MACSQuant VYB flow cytometer that is equipped with three lasers of 
405 nm (violet), 488 nm (blue) and 561 nm (yellow) wavelength (see Table 1). 
 
Table 1: Optical configuration of the MACSQuant VYB. 
The optical configuration of the MACSQuant VYB can be found under: 
http://www.miltenyibiotec.com/en/products-and-services/macs-flow-cytometry/flow-
cytometers/macsquant-vyb/macsquant-vyb.aspx. 
 
 
Samples that were stained with the VioBlue and FITC FRET pair were measured either on the 
MACSQuant VYB or the MACSQUant Analyzer 10. This instrument is equipped with three 
excitation lasers for the wavelength 488 nm (blue), 640 nm (red) and 405 nm (violet) (see 
Table 2).  
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Table 2: Optical configuration of the MACSQuant Analyzer 10. 
The optical configuration of the MACSQuant 10 can be found under: 
http://www.miltenyibiotec.com/en/products-and-services/macs-flow-cytometry/flow-
cytometers/macsquant-analyzer-10/macsquant-analyzer-10.aspx 
 
All calcium influx measurements were performed on a MACSQuant X instrument that is still 
under in-house development at Miltenyi Biotec GmbH. The optical configuration of this 
instrument corresponds to the configuration of the MACSQuant 10. The major difference 
concerning the calcium influx measurement is that the sample uptake is not finished before 
the data acquisition is started and therefore this instrument allows for a continuous sample 
uptake and measurement. Also the PD-1 FRET downscale experiments were measured at 
this instrument, because it allows for faster sample acquisition and is compatible with a 384-
well plate. 
In order to monitor the daily performance of the instruments, the machines were calibrated 
with MACSQuant calibration beads. No compensation was applied for all FRET 
measurements. 
 
4.7.1 Gating strategy 
In order to determine the median staining intensities in the donor, acceptor, and FRET 
channels the following gating strategy had been used: 
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Figure 7: Gating strategy. Median staining intensities were read out by setting a first gate on the scatter parameters andet 
and a second gate on the singlet cells. Based on this target population, ellipse gates were set on the donor versus FRET 
channel and acceptor versus FRET channel double positive populations. 
 
As the very first gate, the target population was defined in the FSC-A versus SSC-A plot based 
on their size and granularity. Using this population, a singlet gate was drawn in the FSC-A 
versus FSC-H plot in order to exclude all doublet cells that might display an increased area to 
height signal. This population was then used to find all donor-positive cells (only in the 
respective positive samples) in the donor channel (here: VioBlue) versus the FRET channel 
(here: VioGreen) and an ellipse gate was set on the double positive population. Next, the 
selected population was analyzed in the acceptor channel (here: FITC) versus the FRET 
channel in order to determine all cells that are positive for the acceptor dye, again only if the 
cells were positively stained. 
 
4.8. The FRET Express Mode workflow 
To simplify the FRET analysis, an “Express Mode” for the automated measurement and 
analysis via predefined settings and algorithms of the determination of the FRET efficiency 
was written. This program is embedded into the MACSQuantify software and was written in 
python programming language. The complete script can be found in the appendix. 
Briefly, the process of the automatic FRET calculation program is the following: 
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Figure 8: Work flow of the automatic FRET calculation program. In the first step, the express mode tests whether the 
sample is gouped or not. In case the sample is grouped, the standard FRET express mode algorithm is started, including 
gating and the FRET analysis. The results are then exported into a CSV file. If the sample is not grouped, the express mode 
algorithm is starting the analysis for one single FRET sample. Here, the CSV file is imported to provide the control values for 
the FRET calculation. Accordingly, the FRET sample is gated for the positive populations and the FRET analysis in done. 
 
In the very first step, the FRET program tests whether the sample that is to be analyzed is a 
grouped sample or not. If the sample is grouped, then it is tested if all required controls are 
included in the samples that are to be measured in this experiment. On all groups, gates are 
set on the target populations according to the gating strategy in 4.7.1 Gating strategyin order 
to determine the required median intensities for the donor, acceptor and FRET channels. 
Next, all control parameters required for the FRET efficiency determination are calculated. 
The results are shown on different analysis pages and the control parameters are stored in a 
comma separated value (CSV) file. 
In the case one samples is not grouped, it is assumed that the sample is a FRET sample that 
is to be analyzed with the program. Therefore, only the gating procedure is applied that is 
used for the FRET positive sample and the control values are imported from the CSV file. 
Based on those values, the FRET efficiency can be calculated and the results are depicted on 
one analysis page. 
The algorithms behind the different functions are explained in detail in the next sections. 
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4.8.1 Import function 
All the main functions of the MACSQuantify software are written in C++. Therefore, serval 
scripts that serve as a basis for the express mode have to be imported in the beginning of 
the script. For example, the os-module (miscellaneous system operating interfaces) is 
required to use the program independent from the operating system. Further basis Express 
Mode functions, like basisScript, utilities, copy, processSample, time, mq and expressModes 
contain important basic algorithms that are required in the Express Modes functions. Some 
of these functions again contain further subfunctions that can be imported separately, like 
for example the function basisGating. 
 
4.8.2 Default settings 
The experimental settings are predefined in the FRET analysis Express Mode. Four different 
samples are required for the FRET calculation: 1) A blank sample is left unstained. It is used 
to determine the background fluorescence of the samples. 2) A donor only sample, in which 
only the donor protein is stained and likewise, 3) An acceptor only sample. Based on 2 and 3, 
the crosstalk between donor and acceptor and also the bleed through into the FRET channel 
can be calculated. 4) A FRET sample, in which both donor and acceptor proteins are stained. 
This sample is the one that is used to calculate the FRET efficiency on.  
The default uptake volume for one sample is set to 100 µl, and the sample volume is set to 
250 µl. Samples will not be mixed before measurement. The flow rate for the measurement 
is set to medium speed with no auto flow rate. No event limit is applied in the default 
settings. All channel annotations can be done manually by the user. The default groups for 
the VioBlue-FITC FRET pair are predefined for the experiment as: 
1: 'Blank', 
2: 'VioBlue_Donor', 
3: 'FITC_Acceptor', 
4: 'VioGreen_FRET' 
For the Alexa Fluor 488 and Alexa 555 FRET pair, those parameters were changed 
accordingly. 
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4.8.3 Automatic gating 
The gating on the target population is defined by several algorithms. Those algorithms can 
be found in the class analyzeFRET where the gating coordinates for all four samples are 
calculated. First all potential preexisting subpopulations are removed and a progress viewer 
for the gating procedure is started. In the express mode, the different samples are called as 
Fractions. Those Fractions are identified via the function retrieveFractions. This function 
automatically returns the different samples, the blank, donor only, acceptor only and FRET 
sample.  
The coordinates for the gates are calculated on the basis of one dimensional histograms. 
Accordingly, for each channel in one dotplot, a separate fluorescence intensity histogram is 
created for the detection of the desired populations. Those histograms consist of 512 
channels. During several smoothing steps and a so-called binning function the median and 
median values of adjacent channels are taken as one new data point. As a consequence, the 
whole histogram is smoothened and therefore reduced in its size and corrected for 
measurement outliers.  
In histograms with defined borders on the X-axis all events that would be out of this range 
are displayed in the first channel on the left side (0), and in the last channels on the 
right  (256), respectively. These events therefore pile up in the direction of the Y-axis. As a 
consequence, all those events would give false results in these channels as described in the 
following. Therefore, in the zeroBounds function all events in these channels are removed. 
Using those two-dimensional histograms, the coordinates for the gates are calculated. For 
this purpose, the function FWHM (full width, half maximum) determines the maximum of 
the histogram, using the peak with the highest number of event counts if more than one 
peak was determined in the histogram. Then the function returns two values, one for the 
left half maximum and one for the right one of a peak. In order to define the left border of 
the peak and therefore a split if a bimodal distribution can be found, the median of the two 
half maxima is determined and subtracted by 3.5 times its standard deviation. 
Using this approach to determine the coordinates of the events for a given parameter, 
several gating functions were developed and implemented in the program standardGating. 
Therefore, several gating functions for the creation of a for example a singlet gate or ellipse 
gate are called up from this program and are used to find the target populations in the FRET 
express mode. The color of the gated region is set in HTML code individually for each gate. 
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4.8.4 FRET calculation 
FRET efficiency is calculated automatically in this program according to the steps described 
in 2.2. At the beginning of workflow of the FRET program, the user is permitted to type in 
the alpha factor manually into the sample description. The value is extracted by using 
regular expression search algorithms in the function getAlphaFromDescription. Alternatively, 
a default alpha value is set to 0.3533 (as determined for the CD3 homoclustering VioBlue 
FITC FRET pair). 
As normally the FRET efficiency would calculated within the script once the program analysis 
was started, no change in FRET efficiency can be updated if the user would change the gate 
positions after the FRET calculation was finished. For that reason, the FRET calculation was 
placed into a textblock module. Textblocks are part of the analysis pages and therefore 
update themselves as soon as the region in a plot is changed. Thus, a new textblock script 
was created which contains all the FRET calulations. It can be assigned in the analysis pages. 
Based on the different fractions (with a small first letter), the median intensity values are 
determined by the program and updated if the gates are changed. 
The median fluorescence intensities are loaded in for the donor, acceptor and FRET channel. 
The FRET efficiency calculation is performed according to the FRET calculation described in 
2.2 FRET Efficiency calculation. 
    
4.8.5 Acquisition page 
During sample measurement, the cell populations and the gates which are set on the target 
populations will be visible. Therefore, the class FRETAquisitionPage is created in the 
beginning. There is a general page template containing all page setups which are based on 
the function basisEasyPage, which can be filled with plots and tables. In this class, first the 
scatter and fluorescence channels are defined from the utilites. The sample which is 
displayed on the page is always the current live sample. Four plots are shown on this page: 
the first one is a dotplot, showing the measured cell population in a FSC-SSC plot. 
Furthermore, the three histograms for donor, acceptor and FRET intensity are depicted here.  
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4.8.6 Analysis pages 
Several different analysis pages give the user detailed information about the samples and 
their FRET efficiency. The analysis pages are based on the same structure as the acquisition 
page, only this time the fluorescence intensity determination and FRET calculation results 
are included in those pages for all four samples. 
Class FRETAnalysePage1 shows the target population on the FSC-SSC dotplot, and the single 
histograms for the donor, acceptor and FRET channel based on the target gate. Also the 
gates on the positive populations in the histogram are displayed. Furthermore, the self-
updating tables created in the textblock are retrieved, thus the median intensity values for 
donor, acceptor and FRET channel are displayed. This page is created for each the blank, 
donor only, acceptor only and FRET sample individually. 
All calculations that are required to determine the FRET efficiency are shown in class 
FRETAnalysePage2. Here, the tables for an overview on all single median intensities, the 
background subtraction, the crosstalk values, the alpha factor input and the FRET efficiency 
result are displayed. These tables are also constructed in the FRET textblock to enable 
calculation updates in case the gates are changed. 
The sixth page, class FRETAnalysePage3, gives the user an overview on all the most 
important results at once. This page includes plots of the FRET sample, showing the target 
gate in the FSC-SSC dotplot and the positive cells in histograms for donor, acceptor and FRET 
channel. Furthermore, tables based on the textblock are included. These tables show the 
median intensities of all the FRET samples, the alpha factor and the overall FRET efficiency. 
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Figure 9: The FRET Express Mode Program. The program provides an output analysis page with information on: (A) the 
automatic gating procedure and the results of FRET efficiency calculation, and (B) shows the FRET efficiency distribution for 
both no activation and T cell activation with 2 µg SEB, including the negative FRET values. From: von Kolontaj et al., 2016 
 
4.8.7 The FRET efficiency histogram 
In order to enable the plotting of a histogram of the FRET efficiency on a cell-by-cell basis, a 
histogram for the FRET efficiency is created based on the calculated values.  
For that, a new FRET efficiency channel has to be integrated into the sample file. However, 
an .mqd file that had once be created cannot be overwritten retrospectively but the 
acquisition of a sample is already finished before the FRET analysis. Therefore, a new .mqd 
file is generated containing a “FRET Efficiency” channel and all other channels that are 
required for a complete FRET analysis. The channels are imported from the .mqd file that is 
to be analyzed, while all the background intensity values and the crosstalk values were 
previously stored in an extension and can be assigned in this class of the script. Next, for 
each single cell the median intensity values for donor, acceptor and FRET channel are 
determined and subtracted by the background intensities. 
The FRET efficiency is then calculated for each single cell as previously described in 4.8.4 
FRET calculation and the new FRET file containing the new FRET channel is created and 
automatically opened in the MACSQuantify Software. 
     
4.8.8 FRET Post Processing Parser 
For screening approaches in which multiple FRET values are to be analyzed in a large scale, a 
FRET Post Processing Parser was written to export the FRET efficiency results into one excel 
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sheet per measured multiwell plate. For this, the Post Processing Parser calls up the FRET 
express mode for each FRET sample that is measured on the plate. The FRET efficiency is 
determined as described previously for each sample and the corresponding result is written 
into one Excel sheet that contains information on the sample name, the Sample ID and 
description as well as the start time, analysis status and the date that the FRET calibration 
was performed. 
 
 
 
Figure 10: Workflow of the FRET Post Processing Parser. In green the functional area of the Post Processing Parser is 
depicted. The Post Processing Parser extends the FRET express mode regarding an additional export function. This function 
is only started if the sample that is to be analyzed was not grouped. As a result, the most relevant values of each FRET 
sample is exported automatically into one excel sheet per analysis run.  
 
4.9 Validation of the FRET Express Mode 
In order to validate the results that are obtained using the FRET Express Mode we developed 
antibody-based FRET calibration beads. For that purpose, we took protein A/G-coated 
polymethyl methacrylate beads and labeled them with the CD3-specific antibody conjugates 
conjugated to Alexa Fluor 488 as the FRET donor fluorophore and to Alexa Fluor 555 as an 
acceptor. Here we varied the donor to acceptor ratios, as it is known that an increased 
acceptor to donor ratio increases the FRET efficiency90. The results achieved using the FRET 
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Express Mode were then compared to the respective results obtained by previously 
published FRET analysis program91. 
 
Figure 11: Validation of the FRET Express Mode program. FRET calibration beads are protein A/G coated polystyrene beads 
that are loaded with different donor to acceptor ratios of Alexa Fluor 488 and Alexa Fluor 555 conjugated CD3-specific 
antibodies. From: von Kolontaj et al., 201611. 
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5. Results 
5.1 Validation of the FRET program with FRET calibration beads 
Data files of FRET calibrations were analyzed in the FRET program and the results were 
compared to the calibration results determined by a previously published program (compare 
4.9 Validation of the FRET Express Mode). 
The FRET efficiency increased among the increase of the acceptor to donor fluorophore 
ratio. We could measure values from 0.5% FRET efficiency for the donor only control up to 
67.7% FRET efficiency for the ratio of 5.7 acceptor antibody conjugates per donor. 
 
 
Figure 12: Increasing amount of acceptor to donor fluorescent molecule ratios lead to an increase in FRET efficiency. 
Here, FRET calibration beads with different acceptor to donor antibody conjugate ratios were analyzed for their FRET 
efficiency. From: von Kolontaj et al., 201611. 
 
The correlation between the program and the FRET calibration was 0.9993 as determined via 
Person correlation with the two-tailed p<0.0001. 
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Figure 13: Validation of the FRET Express Mode using the Pearson correlation for FRET calibration beads compared to 
published calculations. The results were analyzed using the ReFlex program developed and published by Szentesi et al. 
From: von Kolontaj et al., 201611. 
 
 
5.2. CD3-CD4 interaction 
The interaction of the CD3 and CD4 coreceptors was measured by the determination of the 
FRET efficiency after T cell activation and was confirmed by colocalization analysis on the 
confocal microscope. 
 
5.2.1 CD3-CD4 FRET 
We could detect the interaction of CD3 and CD4 on T cells after the activation of PBMCs with 
SEB. Here, a CD3-specific VioBlue antibody conjugate and a CD4-specific FITC antibody 
conjugate were used. Due to the crosslinking of the SEB of the TCR with the MHCII on the 
antigen presenting cells, the T cells were stimulated unspecifically. This causes a strong 
activation of the T cell that is marked by structural rearrangements of the receptors on the 
cell surface. 
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Figure 14: FRET Efficiency for CD3 and CD4 coreceptor clustering after no stimulation or 2 µg SEB superantigen stimulation 
for two minutes or five hours, ** P < 0.01. From: von Kolontaj et al., 201611. 
 
The FRET efficiency increased significantly after the short 2 minute activation from 
12.5 ± 0.3% to 16.3 ± 0.6% (ANOVA, P = 0.0016). After 5 hours of SEB stimulation, the FRET 
efficiency decreased again significantly to 10.6 ± 1.2%. 
 
5.2.2 CD3-CD4 CLSM colocalization and correlation 
In order to prove that the results of the CD3-CD4 FRET system are not only an artifact, but 
can be further confirmed via another method, the colocalization of CD3 and CD4 was 
analyzed via confocal laser scanning microscopy (CLSM). Here PBMC, which were stained, 
activated with SEB and fixed with paraformaldehyde were imaged under the CLSM and 
analyzed for colocalization. As positive colocalization control, both CD3 and the TCR as a 
complex and CD3 and CD45 without SEB treatment were included in the experiments. As a 
negative control, the colocalization of CD3 and CD4 after SEB treatment was analyzed. 
For colocalization analysis, the cells were analyzed with the colocalization tool of the Zeiss 
ZEN2010 software (see 2.8). For comparison with the FRET program results in a graph, the 
axes had to be adapted. Therefore the results of the FRET program were first plotted against 
the results of the colocalization tool. The formula of a regression line between those results 
(y = 3.604x + 18.482) was used to normalize the FRET program results according to the 
colocalization tool results. Then both results could be compared in one curve. It can be seen 
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that the scope of both the CLSM colocalization and the FRET analysis program results are 
very similar.  
 
 
Figure 15: Comparison between the colocalization coefficient (overlap coefficient after Manders) for CD3-FITC and CD4-
APC and the normalized FRET efficiency. As colocalization controls, the colocalization of CD3 and the TCR or CD3 and CD45 
(no activation) had been used as a positive control, whereas the colocalization of CD3 and CD45 after 2 µg SEB activation for 
1 hour had been used as a negative control. From: von Kolontaj et al., 201611. 
 
On the images it can be seen that the not activated T cells show an equal and regular 
distribution of CD3 and CD4 on the cell surface. After the short activation with SEB, 
microclusters of CD3 and CD4 begin to form. Here, a large proportion of the cell surface is 
colored in yellow, indicating that FITC and APC are measured in the same pixel. After five 
hours of SEB incubation, CD3 forms large clusters on the T cell surface. Furthermore, much 
CD3-FITC signal can be found inside the cells while CD4-APC fluorescence is strongly 
decreased.  
 
 
Figure 16: Confocal images of CD3-FITC (green) and CD4-APC (red) stained receptors on the cell surface for no activation 
or two minute/five hour 2 µg SEB activation. From: von Kolontaj et al., 201611. 
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The segregation of CD45 from the immunological  synapse and from the CD3 coreceptor 
could be seen on the fluorescent images (colocalization negative control). In the positive 
controls, the CD3 receptor signal is colocalizing with both the CD45 receptor and the TCR. 
 
Figure 17: Colocalization controls. The confocal images show the colocalization of CD3 and CD45, either (A) after 2 µg SEB 
activation (negative control) or (B) without SEB activation (positive control). Another positive control was (C) the 
colocalization of the CD3ε-chain and the TCRαβ receptor. Anti-CD3-FITC is shown in green, anti-CD45-APC in red and 
anti-TCRαβ-APC also in red. From: von Kolontaj et al., 201611. 
 
Results 
 
46 
 
5.3. CD3 homoclustering 
It was described that immediately after T cell activation, the CD3 coreceptor is clustering in 
lipid rafts to form the immunological synapse. This was proven by measuring the increase in 
FRET efficiency for CD3 homoclustering after T cell activation or the respective inhibited 
increase in immunocompromised patients. The T cell activation and the structural 
rearrangements were furthermore confirmed by cytokine secretion assays, compared to 
intracellular calcium influx and disturbed with substances that change the lipid raft integrity. 
 
5.3.1 CD3 homoclustering FRET 
The clustering of the CD3 coreceptor after SEB stimulation was analyzed via antibody 
conjugates that were directed against the CD3 coreceptor for both the donor and the 
acceptor dye. Two different FRET pairs were used: either VioBlue with FITC or Alexa Fluor 
488 with Alexa Fluor 555. The FRET efficiency increased significantly increase (ANOVA, P = 
0.0011 for the VioBlue and P = 0.0332 for the Alexa FRET pair) after a 2 minute SEB 
activation from 4.9 ± 0.2% to 10.4 ± 0.8% (VioBlue FRET pair) or from 4.8 ± 0.1% to 8.0 ± 0.4 
% (Alexa FRET pair)  during cluster formation.  
 
 
Figure 18: T cell inhibition by SEB superantigen blocking antibody. (A) Schematic view of the SEB-specific antibody 
inhibition. (B) CD3 coreceptor homoclustering and activation validation using the FRET pair VioBlue and FITC or Alexa Fluor 
488 and Alexa Fluor 555, showing the FRET efficiencies for no activation, two minute 0.2 µg SEB activation or 0.2 µg SEB 
blocked with the 0.5 µg SEB-specific antibody either after a three-hours pre-incubation or added with the SEB in parallel to 
the cells. From: von Kolontaj et al., 201611. 
 
We could inhibit the increase in FRET efficiency by adding a SEB-specific blocking antibody 
that is binding to the SEB domain that would normally crosslink to the TCR (Figure 18 A). For 
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these experiments, the antibody was either preincubated with the SEB (SEB blocking), 
leading to a reduction in FRET efficiency to E = 6.6 ± 0.8% (VioBlue FRET pair) and E = 6.0 ± 
1.0 % (Alexa FRET pair) or added to the PBMCs in parallel with the SEB (SEB + Blocking AB),  
reducing the FRET efficiency to 7.9 ± 0.2% FRET efficiency (VioBlue FRET pair) and in E = 5.6 ± 
0.3% (Alexa FRET pair)(see Figure 18 B).   
 
5.3.2 Cytokine secretion 
The cytokine secretion of PBMCs that were stimulated with SEB over night was analyzed to 
confirm the activation of the T cells. 
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Figure 19: Cytokine secretion of activated T cells. Human PBMCs were activated with 1 µg SEB and cultured over night. The 
cytokine expression was determined using the MACSPlex cytokine secretion kit. Results of most relevant cytokines, n = 3, 
technical replicates. From: Kolontaj et al., 201611. 
 
The most relevant cytokines that indicate for T cell activation, namely GM-CSF, IFN-γ, IL-2, IL-
6 and TNF-α were analyzed for their concentration in the supernatant. While almost no 
cytokines could be detected if the PBMCs were not activated, the concentration was strongly 
increased after T cell activation. GM-CSF showed a median concentration of 
732.67 pg/ml ± 36.29, IFN- γ a concentration of 13377.13 pg/ml ± 943.53, IL-2 17160 pg/ml 
± 720.31, IL-6 2576.87 ± 81.88 and TNF-α a concentration of 9014.4 pg/ml ± 404.89. 
Results 
 
48 
 
5.3.3 Calcium Influx versus FRET efficiency as activation marker 
The increase in intracellular calcium after T cell activation was determined via the eFluor514 
intensity increase and compared to the results obtained via measuring FRET. Here, the 
PBMCs were stimulated either with SEB or by using the TransAct activation kit 30 seconds 
after the acquisition of the measurement was started.  
 
 
Figure 20: Time course measurement of FRET efficiency for the clustering of the CD3 coreceptor, compared to calcium 
influx measured by eFluor514 intensity after 2 µg SEB or 0.5 µg TransAct CD3/CD28 Kit activation. From: von Kolontaj et 
al., 201611. 
 
The maximum FRET efficiency after both SEB and TransAct kit stimulation was reached  
almost immediately after T cell activation at the time point 60 seconds. Here, the maximum 
FRET increase over baseline was 0.84 ± 0.09 for SEB stimulation and 0.70 ± 0.12 for TransAct 
activation. The intracellular calcium influx reached its maximum intensity at a later time 
point. At the time point 120 seconds the plateau for the maximum calcium dye intensity was 
reached almost equally for SEB stimulation (0.82 ± 0.1 increase) and TransAct bead 
activation (0.7 ± 0.19 increase).  
 
5.3.4 CD3 clustering as diagnostic tool for immunodeficiencies 
The homoclustering of the CD3 coreceptor on immunodeficient patients compared to 
healthy individuals using FRET assay with the Alexa Fluor FRET pair. All patients were 
suffering from defects affecting the dynamic structural rearrangement of the CD3 receptor 
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on the cell surface. For the PBMCs of healthy individuals, the FRET efficiency increased from 
5.9 ± 0.5 to 9.4 ± 0.4 after SEB stimulation of the T cells. 
 
 
Figure 21: Detection of different immunodeficiencies in patients using FRET Express Mode and analyzing the clustering of 
the CD3 coreceptors after treatment with 2 µg SEB. Patients were suffering from a DOCK8-deficiency, the Wiskott-Aldrich-
Syndrome or a MHCII-deficiency. From: von Kolontaj et al., 201611. 
 
For the immunocompromised patients, no increase in FRET efficiency could be detected 
after SEB activation. The patients suffering from a DOCK8 syndrome showed a change in 
FRET efficiency from 5.2 ± 0.3 to 4.0 ± 0.7 after the PBMCs were treated with SEB. The FRET 
efficiency of patients affected by the Wiskott-Aldrich-Syndrome changed from 5.4 ± 0.6 to 
4.7 ± 0.4, and patients suffering from a MHC class II deficiency had a change in FRET 
efficiency from 5.8 ± 0.4 to 5.2 ± 0.3.  
 
5.3.5 Lipid raft disruption 
The integrity of lipid rafts of T cells was tested via the CD3 homoclustering FRET assay after 
different chemical treatments. Here, T cells were either not activated, stimulated with SEB 
for 1h and treated with bCD or cholesterol. 
When measuring the median intensities of the donor (VioBlue), acceptor (FITC) and FRET 
channel (VioGreen), it could be observed that the intensity mostly did not change regardless 
of the T cell treatment (compare Figure 22). The mean VioBlue fluorescence intensity was 
6.1 ± 0.23 when the T cell was not activated, 5.77 ± 0.53 after SEB activation, 6.01 ± 0.34 
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after SEB and bCD treatment. In a similar way, also the values for FITC hardly changed 
(14.09 ± 0.00, no activation; 12.41 ±0.01, SEB activation; 13.02 ±1.23, SEB and bCD) and 
VioGreen (4.09 ± 0.12, no activation; 3.94 ±0.23, SEB activation; 3.77 ±0.28, SEB and bCD). 
Only the cells that were treated with cholesterol showed higher fluorescence intensities in 
all the fluorescent channels (VioBlue: 8.06 ± 0.04, FITC: 15.54 ± 0.93, VioGreen: 4.99 ± 0.07). 
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Figure 22: Mean fluorescence intensity of VioBlue, FITC and VioGreen after different T cell treatments affecting the lipid 
raft integrity. n=2 biological replicates. 
 
However, when comparing and calculating the FRET efficiencies after the different 
treatments, it could be measured that after SEB activation, the FRET efficiency increased 
from 4.03% ± 0.51 to 5.73 ± 0.34. After treatment with bCD, the FRET efficiency was strongly 
decreased to -1.5 ± 3. When the PBMC were treated with cholesterol, the FRET efficiency 
was 2.5 ± 1.43 and therefore comparable to the FRET efficiency measured if the T cell was 
not activated.  
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Figure 23: FRET efficiency after T cell stimulation via SEB and bCD or cholesterol treatment for n=4 blood donors. The 
diagram shows the correlation between lipid raft integrity and the corresponding FRET efficiency for CD3 homoclustering. 
 
In the next experiment, the FRET efficiency was determined over a time course of three 
hours. Here, also a T cell sample that was treated with nystatin was included. 
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Figure 24: FRET efficiency after 0-3h treatment of T cells with SEB or other substances that are known to have an impact 
on lipid raft integrity. FRET efficiency was determined for CD3 homoclustering after the given time intervals. 
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The increase in FRET efficiency was highest for the PBMCs that were stimulated with SEB and 
not treated any further (from 4.84% to 29.3%). T cells that were stimulated with SEB and 
treated with nystatin or bCD showed a similar increase in FRET efficiency as the T cells that 
were not activated at all (to 19.0 for no activation, 17.5% for SEB and bCD and 20.6% for SEB 
and nystatin). Only T cells that were activated with SEB and treated with cholesterol almost 
showed no increase at all in FRET efficiency when comparing the time points 0 h (4.84% FRET 
effocoemcy) to 3 h stimulation (9.6% FRET efficiency). 
 
5.3.6 Long term dynamic rearrangement of the CD3 coreceptor 
In order to analyze the long-term changes in FRET efficiency, PBMCs were stimulated with 
SEB for the given time points and either stained with the VioBlue and FITC FRET conjugates 
before or after the stimulation. 
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Figure 25: Long-term changes in FRET efficiency, compared to the median fluorescence intensity of VioBlue and FITC after T 
cell stimulation with SEB. The cells were either stained for CD3 with the FRET antibody conjugates before or after SEB 
stimulation for the given time points. 
 
We could observe a constant increase in FRET efficiency over time in case the T cells were 
stained with the antibody conjugates before SEB stimulation. Here, the FRET efficiency 
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constantly increased from 5.7% ± 1.1 up to 13.0% ± 1.3.However, if the T cells were stained 
after the T cell stimulation for the indicated time points and were analyzed for FRET, the 
FRET efficiency after 5 hours of stimulation (4.9% ± 1.4) was comparable to the FRET 
efficiency that was determined if the cells were not activated (4.9% ± 1.4). Only for a very 
short period of time (1h) after T cell activation, an increase in FRET efficiency could be 
measured, where the FRET efficiency increased to 6.45% ± 0.55.  
This effects could be supported by determining the median fluorescence intensity of the 
VioBlue and FITC conjugates (
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Figure 25 B). When the T cell was stained before stimulation, the FITC median intensity 
constantly decreased over time (from 16.05 ± 3.36 to 12.36 ±3.17 after 5 h). This effect was 
even more pronounced for the VioBlue conjugate. Here the decrease in intensity was even 
stronger, with the median VioBlue intensity decreasing from 10.62 ± 0.98 at time point 0 to 
4.59 ±1.4 after 5 h of stimulation. When the T cells were stained after stimulation, no 
decrease in fluorescent intensity for both the VioBlue and FITC conjugate could be observed. 
The median fluorescent intensity was 10.63 ± 0.99 (VioBlue) and 16.05 ± 3.36 (FITC) at time 
point 0, and 10.76 ± 0.68 (VioBlue) and 15.87 ± 3.26 (FITC) after 5 hours of SEB stimulation. 
 
5.4 Immune checkpoint inhibition 
For immune checkpoint inhibition, the clustering of CD3 with PD-1 was determined via FRET 
using the FITC and VioBlue FRET pair. 
 
5.4.1 PD-1 expression on T cells 
PD-1 expression after T cell stimulation was determined for PBMCs of two blood donors and 
evaluated for the percentage of PD-1-positive cells and PD-1 median intensity. 
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Figure 26: PD-1 expression on T cells after SEB stimulation as assessed via staining with an anti-PD-1 fluorescent antibody 
conjugate. The proportion of positively stained cells is compared to the median fluorescence intensity. 
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Both blood donors responded slightly heterogeneously to SEB stimulation regarding their 
expression of PD-1. However, we could observe an increase in the amount of PD-1 positive 
cells for both donors the longer the PBMCs were stimulated with SEB from 10.82% ± 1.18 
positive cells at day 1 to 24.21% ± 4.5 PD-1 positive cells at day 4. If the cells were not 
stimulated with SEB, the amount of PD-1 positive cells remained constant with 6.56% ± 0.66 
PD-1 positive cells at day 1 and 4.58% ± 4.48 positive cells at day 4. Also the PD-1 intensity 
increased from 4.15 ± 0.13 at day 1 to 5.4 ± 0.2 at day 4. If the T cells were not activated, the 
PD-1 intensity remained relatively constant from day 1 (3.56 ± 0.08) to day 4 (3.75 ± 0.35) 
 
5.4.2 PD-L1 and PD-L2 expression on antigen presenting tumor cell lines 
In order to find the best antigen presenting cell line to induce PD-1 expression and its 
clustering with the CD3 coreceptor on T cells, several cell lines were screened for PD-L1 and 
PD-L2 expression.  
 
Figure 27: PD-L1 and PD-L2 expression on different tumor cell lines. Different tumor cell lines were stained with anti PD-L1 
and PD-L1 fluorescence antibody conjugates and the proportion of positive cells as well as the median fluorescence 
intensity is shown. 
 
We found the cell line MDA-MB-231 the highest PD-1 ligand expressing cell line for both PD-
L1 and PD-L2. Here, almost all cells were tested to be positive for PD-L1 (95.42%) and PD-L2 
(95.62%), compared to all other cell lines, that did not exceed 10% positive cells for both PD-
L1 and PD-L2. Also the median fluorescence intensity was highest for the MDA-MB-231 cell 
line with a median intensity of 19.22, compared to a median intensity ranging from 5.13 to 
0
10
20
30
40
50
60
70
80
90
100
PD-L1 % pos PD-L1 median PD-L2 %pos PD-L2 median
MDA-MB-231
Jurkat
Raji
Ramos
K562
Results 
 
57 
 
8.3 for all other tested cell lines. The marker PD-L2 was found to be not that highly 
expressed on all cell lines. Here, the median fluorescent intensity ranged from 2.33 to 3.85 
for all cell lines. 
 
5.4.3 T cell isolation and its effect on FRET efficiency 
To validate that the increase in FRET efficiency after stimulation with SEB is derived from 
structural rearrangements of the receptors on the T cell and not any other cell type that can 
be found in PBMCs, different separation methods and treatments of T cells were tested 
here. For this, the T cells were separated using two different approaches: the Pan T cell 
isolation kit and the DC isolation kit that was modified into a depletion kit. The cells were 
either cultivated as PBMCs, as pure isolated T cells or in co-cultivation with the tumor cell 
line MDA-MB-231 and either stimulated with SEB or left untreated. 
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Figure 28: FRET efficiency for CD3 and PD-1 clustering after different T cell isolation protocols and under different culture 
conditions for n = 3 biological replicates. The T cells were either plated as complete PBMC or isolated according to the 
isolation kits described above and co-cultured with the MDA-MB-231 tumor cell line +/- SEB as indicated. 
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We could measure that for pure T cells the treatment of SEB could increase the FRET 
efficiency only marginally (from 3.8% ± 0.07 to 6.52% ± 1.28 for Pan T cell isolation and from 
5.2% ± 0.08 to 5.6% ± 0.18 for the DC depletion protocol). The increase is less pronounced 
than the increase in FRET efficiency that can be observed for the treatment of PBMCs with 
SEB (from 0.99% ± 0.04% to 5.97% ± 0.1. Co-cultivation of the T cells with the tumor cell line 
MDA-MB-231 even further decreased the FRET efficiency if the T cells were not activated. 
Here the FRET efficiency was 4.57% ± 0.64 for Pan T cell isolation and 3.44% ± 0.1 for the DC 
depletion protocol. However, as soon as the T cells were both co-cultivated with MDA-MB-
231 cells and stimulated with SEB, the FRET efficiency increased strongly to 9.64% ± 0.36 for 
the Pan T cell isolation kit and to 10.24 ± 0.01 for the DC depletion protocol. 
 
5.4.4 PD-1 CD3 FRET and PD-L blocking 
In the next test, the PD-1 ligands PD-L1 and PD-L2 were blocked using specific blocking 
antibodies and the impact on the fluorescence intensity of PD-1 and the FRET efficiency for 
CD3-PD-1 clustering on PBMCs was determined.  
 
 
Figure 29: Blocking of PD-L1 and PD-L2 and the impact on PD-1 median fluorescence intensity (A) and PD-1 CD3 FRET (B). 
n = 4 biological replicates. PBMCs were stimulated with SEB and either treated with the anti PD-L1 and PD-L1 blocking 
antibodies or left untreated. 
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The median fluorescence intensity for PD-1 was comparable for both conditions. T cells that 
were stimulated with SEB showed a fluoresce intensity of 4.74% ± 0.21, and T cells that were 
both stimulated with SEB but treated with PD-L1 and PD-L2 blocking antibodies had a 
median fluorescence intensity for PD-1 of 4.58% ± 0.33. However, when the same cells were 
analyzed for their FRET efficiency for PD-1 and CD3 clustering, the FRET efficiency for SEB 
activation only was higher (E = 21.7% ± 1.45), p = 0.05) than for the cells that were 
furthermore treated with the PD-1 ligand blocking antibodies ( E = 16.4% ± 0.53). 
 
5.4.5 Impaired signaling on T cell lines 
Cell lines do normally not show such a high donor variation as primary cells do and 
furthermore they have the advantage that they are easier to obtain and to culture in large 
scales. For that reason, the clustering of CD3 and PD-1 was determined by measuring FRET 
on two different T cell lines, namely Jurkat cells and HuT-78 cells. 
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Figure 30: FRET efficiency for the CD3-PD-1 interaction on Jurkat cells after SEB stimulation for n = 3 technical replicates. 
Jurkat T cells were co-cultured with MDA-MB-231 cells and treated with SEB as indicated. 
 
On Jurkat cells, the FRET efficiency did not increase when the pure Jurkat cells were 
stimulated with SEB (E = 14% ± 0.58 for no activation and E = 13% ± 3.06 FRET when treated 
with SEB. The FRET efficiency further decreased when the Jurkat cells were co-cultivated 
with MBA-MB-231 cells to 0.33% ± 0.82 FRET efficiency. After co-cultivation with the tumor 
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cell line and SEB stimulation, the FRET efficiency was still decreased compared to untreated 
Jurkat cells (E = 5% ± 1.53). 
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Figure 31: FRET efficiency for CD3-PD-1 interaction on HuT-78 cells after SEB stimulation for n = 3 technical replicates. 
Here, HuT-78 T cells were co-cultured with MDA-MB-231 cells and treated with SEB as indicated. 
 
A similar effect could be observed for the HuT-78 T cell line. Also here the FRET efficiency 
decreased from 2.57% ± 1.07 to -1.33% ± 1.2 when the pure HuT-78 cells were treated with 
SEB. After co-cultivation with MDA-MB-231 cells the FRET efficiency further decreased to 
E = -2.93% ± 0.97. When the HuT-78 cells were co-cultured with the tumor cell line and 
treated with SEB, FRET efficiency was still decreased with 2.3% ± 1.23 FRET efficiency 
compared to untreated pure HuT-78 cells. 
 
5.4.6 Downscale of the PD-1 CD3 FRET assay for a screening approach 
As the PD-1 FRET assay should allow for a compound screening on substances that inhibit 
the clustering of CD3 with the PD-1 receptor on T cells and therefore rescue the immune 
response, the assay was transferred to buffy coats instead of whole blood and downscaled 
to a 384-well plate format. T cells were isolated from the buffy coats using the Pan T cell 
isolation kit. 
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Figure 32: FRET efficiency for CD3 and PD-1 clustering in the downscaled screening approach. For two different blood 
donors (buffy coats), each n = 3 technical replicates. The isolated T cells were co-cultured with MDA-MB-231 cells and 
treated with SEB as indicated. PD-L1 and PD-L1 were blocked via specific antibodies in case of (+AB). 
 
Here the FRET efficiency increased for both blood donors when the T cells were co-cultured 
with the MDA-MB-231 cell line from 0.07 ± 0.01 to 0.13 ± 0.02 (donor A) and from 
0.06 ± 0.01 to 0.13 ± 0.01 for donor B, respectively. When the T cells were co-cultivated with 
the tumor cell line and activated with SEB, the FRET efficiency further increased to 
0.19 ± 0.03 (donor A) and 0.24 ± 0.01 (donor B). This increase in FRET efficiency could be 
inhibited when the cells were treated with blocking antibodies directed against PD-L1 and 
PD-L2. Here, the FRET efficiency was decreased again to 0.06 ±0.01 for donor A and 
0.13 ± 0.01 for donor B. 
Confocal images confirmed a slightly increased PD-1 expression when the T cells were 
co-cultured with MDA-MB-231 tumor cells (see Figure 33). However, hardly any areas that 
are double positive for both markers (orange) can be found here. After an additional SEB 
stimulation the PD-1 expression further increased and the proportion of colocalization 
seemed higher compared to non-activated T cells. When the T cells were treated with the 
blocking antibodies directed against the ligands of PD-1, PD-1 expression was still high. 
However, the distribution of this receptor seemed more diffuse and did not correlate with 
the CD3 receptor location. 
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Figure 33: Confocal analysis of CD3 and PD-1 colocalization after different treatments. PD-1 was stained with a 
FITC-conjugated antibody (green) and CD3 with an APC-conjugated antibody (red). 
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6. Discussion 
 
6.1 FRET analysis program validation 
To validate the results that were generated using the FRET express mode, we produced FRET 
calibration beads that had different molecular ratios of donor to acceptor antibody 
conjugates. As it could be expected according to Fábián et al.90, the FRET efficiency increased 
with the increase of acceptor to donor ratio, as there is a higher likelihood for the energy to 
be transferred from a donor molecule to an acceptor molecule. 
The results of the FRET analysis program for the calibration beads were also highly 
comparable to the results obtained via conventional FRET analysis as here the ReFlex FRET 
analysis program had been used4. Due to the high correlation of 0.9993, we could show that 
the results that are obtained using the FRET analysis program are precise and therefore the 
program can be used for the evaluation of biologic questions on molecular interactions92. 
 
6.2 CD3 and CD4 interaction 
The FRET program was used to determine the interaction between the T cell receptor/CD3 
complex and the CD4 coreceptor after SEB activation of human T lymphocytes. We could 
prove that the FRET efficiency for the FITC and VioBlue FRET pair increased after stimulation, 
as the SEB unspecifically crosslinks the MHCII receptor of the APC and the TCR/CD3 complex 
on the T cell, causing structural rearrangements on the cell surface.  
Yet, in all the analyses, doublet cells were excluded. The reason for this is that because 
during measurement on the flow cytometer, the interacting cells are pulled apart by the 
sheath fluid and are therefore present as single cells during sample acquisition.  
In general, differences in the FRET efficiency results between the individual blood donors 
were measured. This can be explained by individual expression level of the Vβ3 chain93 on 
the leukocytes of each blood donor. As SEB is binding to this specific TCR chain, the more 
Vβ3 chains are expressed by one donor, the stronger is the T cell activation by 
Staphylococcal enterotoxin B and therefore the FRET efficiency increased. Furthermore, as 
SEB only activates approximately 30% of the total T cell population94, the FRET efficiency 
median results here only represent the average of the overall increase in FRET efficiency for 
the total T cell population of one blood donor and not specifically for the T cells that were 
Discussion 
 
64 
 
activated via SEB. This further explains the reason why the increase in FRET efficiency is not 
highly pronounced in this model.  
 
6.2.1 Colocalization on the confocal laser scanning microscope 
The colocalization of the CD3 coreceptor and CD4 receptor on T cells that were activated 
with SEB was also analyzed via confocal laser scanning microscopy. Here, the CD3 coreceptor 
was stained with a FITC conjugate and CD4 receptor with an APC conjugate. In general, the 
scope of the curve for both the FRET efficiency and the colocalization coefficient for the 
colocalization of CD3 and CD4 before and after SEB stimulation were highly comparable, 
indicating that the FRET assay is an adequate assay to determine molecular interaction. This 
is further supported when the colocalization controls are taken into account. Here, the 
colocalization coefficient results for the 2 minute SEB stimulation for the CD3 and CD4 
interactions are approaching the value of the positive controls (CD3 and CD45 or CD3 and 
TCRαβ without SEB stimulation) and after 5 hours of SEB stimulation, the colocalization 
coefficient is comparable to the negative colocalization control values (CD3 and CD45 after 
SEB stimulation for no colocalization). However, here the great advantage of this method is 
that the determination of molecular interactions using the FRET assay is much more 
accurate than determining colocalization on the confocal microscope, as the resolution of 
the FRET assay is much higher with approx. 10 nm compared to approx. 200 nm on the 
confocal microscope95. 
Additionally, the confocal images revealed phenotypic changes of the receptor distribution 
after SEB stimulation. When the T cell was not activated, the CD3 and CD4 receptors were 
regularly distributed on the cell membrane. After the short activation with SEB for two 
minutes, small activation clusters of CD3 and CD4, so called microclusters, begin to form. 
However, as the resolution of the confocal microscope is not high enough to determine such 
small distances, the changes are hardly visible by eye. Yet, this difference can precisely 
determined via FRET, as here the FRET efficiency increased significantly. After five hours of 
incubation, large clusters of the CD3 coreceptor have formed. They build up the 
immunological synapses to the antigen presenting cells. The CD4 receptor staining is very 
dim in this picture, indicating that most of the CD4 coreceptor was internalized and 
degraded inside the cell. This further supports the strong decrease in FRET efficiency after 5 
hours of SEB stimulation. 
Discussion 
 
65 
 
Altogether, this comparison between the FRET assay and colocalization analysis on the 
confocal microscope shows that there are no artifacts produced by FRET analysis for protein-
protein interactions, but instead that the FRET analysis is a much more specific assay than 
the colocalization measurement on the confocal laser scanning microscope. 
 
6.3 CD3 homoclustering FRET 
The homoclustering of the CD3 receptor after T cell activation via SEB was determined using 
two different FRET pairs, VioBlue with FITC as well as Alexa Fluor 488 with Alexa Fluor 555. 
The data shows that for both FRET pairs, we can measure an increase in FRET efficiency after 
T cell stimulation that is caused by the reduced spatial distance between the CD3 receptors 
during the formation of the CD3 nanoclusters. Furthermore, the increase in FRET efficiency 
can be blocked when a blocking antibody that is specifically directed against the T cell 
binding domain of the SEB molecule88. This effect is not only pronounced when the SEB is 
pre-incubated with the blocking antibody before it is added to the T cells, but also to a lesser 
extend inhibits the T cell activation when the blocking antibody is added in parallel with the 
SEB to the cells. This indicates for a successful inhibition of T cell activation due to the 
blocking antibody that can also be determined using the FRET assay. Therefore, we could 
show that determining T cell activation using CD3 homoclustering FRET is a sensitive and also 
precise tool. 
Differences between the two different FRET pairs regarding the absolute FRET efficiency 
results are likely to be due to biological differences, as both FRET pairs are normalized in the 
FRET calculation for relative energy transfer and the flow cytometer instrument is calibrated 
on a daily routine.  
 
6.3.1 CD3 homoclustering versus T cell activation measurements 
When we compared the FRET assay to other common methods that are used to determine T 
cell activation, we could show that the increase in FRET efficiency is indeed induced by the 
structural rearrangements as the T cell is activated here that are required to trigger 
intracellular T cell activation signaling. 
We determined the cytokine secretion by using the MACSPlex cytokine secretion kit. Here 
we could measure an increase in secreted cytokine concentration after 24 stimulation with 
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SEB. The measured cytokines GM-CSF, IFN-γ, IL-2, IL-6 and TNF-α are positively correlated 
with T cell activation. Therefore, the increase in cytokine concentration that the T cell was 
successfully activated via SEB and that the T cell activation determined here also correlated 
with the activation status of the T cell that was determined via FRET. 
Likewise, we determined the calcium influx into the cytoplasm as this method is commonly 
used as one of the very early cell activation markers. Here, eFluor 514 calcium indicator dye 
was used to measure the relative calcium influx into the cytoplasm of the T cell. For that 
reason, different activation methods were compared. First, the cells were stimulated with 
SEB as described previously. Furthermore, the T cells were activated with the TransAct 
beads, which have the CD3 and CD28 antibodies coupled onto two separate nanobeads. It 
was expected that their special features facilitate the clustering of CD3 and CD28 on the cell 
membrane and lead to strong T cell activation96. We could observe that for those two T cell 
activation methods both the FRET efficiency and the calcium intensity increased. However, 
the increase in FRET efficiency was even faster than the calcium influx. This can be explained 
by looking at the order of structural rearrangements taking place after T cell activation. 
Indeed, the formation of the CD3 microclusters that we could measure via FRET is required 
to trigger the calcium influx into the cell97. For that reason, we concluded that the CD3 
homoclustering FRET assay is not only an adequate tool to measure T cell activation, but that 
it is working in an even faster fashion than intracellular calcium influx measurements.  
 
6.3.2 CD3 clustering as a diagnostic marker 
After we could validate that we can use the FRET assay measuring the homoclustering of the 
CD3 coreceptor to successfully determine T cell activation, we tested if we could also detect 
defects in the structural rearrangements in immunocompromised patients using this FRET 
assay. In healthy control samples, the increase in FRET efficiency after SEB activation was 
strongly pronounced as it was in the last experiments. But indeed, we could not measure the 
increase in FRET efficiency after T cell stimulation with SEB for patients suffering from 
diseases that impair cytoskeletal rearrangements (DOCK8-deficiency and Wiskott-Aldrich-
Syndrome) or even more upstream are impaired in a proper activation of the T cell (MHCII-
deficiency patients).  
Therefore, the CD3 homoclustering FRET assay can be used to detect defects in structural 
rearrangements also in clinical settings. 
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Common laboratory tests for those diseases include for example immune globulin level 
determination, functional tests of the immune cells and genetic sequencing98.  
However, those tests are usually time laborious and have a high workload on the personnel. 
An automated FRET assay that detects impairments in the structural rearrangements might 
offer a fast alternative and simple alternative for the diagnosis of those diseases. 
 
6.3.3 Lipid raft manipulation 
The CD3 coreceptor is described to be organized in lipid rafts. Lipid rafts are built up mainly 
from cholesterol and play a major role in the organization of cell surface proteins and 
receptors. We manipulated those lipid rafts via different substances that are described to 
have an impact on the concentration or fluidity of cholesterol in order to determine the 
impact of the lipid raft integrity on CD3 homoclustering as measured via FRET. First, we 
compared the mean intensity values for the CD3 coreceptor staining for the FITC and VioBlue 
conjugate and also in the VioGreen channel. Here it was obvious that for all treatments (no 
activation, SEB activation and bCD) the intensities were comparable, so the general 
expression level of the receptor did not change. Only when the cells were treated with 
additional cholesterol, all intensities were slightly increased, but only to a small extend. This 
might be caused by the high concentration of cholesterol that may slightly inhibiting the 
recycling process of the CD3 receptor99. 
However, when we dissolved the lipid rafts using bCD49, the we could observe that the FRET 
efficiency was strongly decreased, even compared to non-activated T cells. The bCD might 
therefore have increased the distance between the CD3 molecules on the cell surface, so 
that they cannot successfully transfer the energy between the single FRET dyes anymore. For 
that reason, it can be concluded from this experiment that already before T cell activation, 
the CD3 molecules are pre-arranged in smaller clusters in lipid rafts, that will form larger 
clusters as soon as the T cell is activated100. On the other side, when the cells were treated 
with cholesterol, the FRET efficiency after SEB stimulation was comparable to the one 
measured when the T cell was not activated at all. It is described that high concentrations of 
cholesterol may decrease the fluidity of lipid rafts101. As a consequence, this might impair 
the CD3 molecules within the lipid rafts in being arranged into close spatial distance after T 
cell stimulation and therefore to no increase in FRET efficiency.  
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In the next experiment we analyzed the long-term effect of lipid raft manipulation over 3 
hours. Here, we also included nystatin to change the lipid raft behavior. Nystatin chelates 
the cholesterol molecules within the lipid raft and therefore deregulates its structure. Here, 
all the different treatments (bCD, cholesterol, nystatin) that disrupt the lipid raft integrity, 
reduced the FRET efficiency after SEB stimulation compared to no lipid raft treatment. This 
effect was even more pronounced after a longer period of time of 2 to 3 hours. 
Therefore, the FRET data do not only supports that the CD3 receptor is located and 
organized within lipid rafts. The CD3 homoclustering FRET assay can also be used to reveal 
those minor structural changes that are derived from varying lipid raft integrities on the cell 
surface. 
 
6.3.4 CD3 homoclustering and long-term dynamic rearrangements 
When we analyzed the change in FRET efficiency for CD3 homoclustering after long term 
stimulation of T lymphocytes with SEB, we could observe that the FRET efficiency constantly 
increased among with an increased stimulation of the cells while the median fluorescence 
intensity of the FRET dyes decreased over time. However, we could only measure this effect 
when we stained the T cells before stimulation. In contrast, when we stained the T cells after 
stimulation immediately before the flow cytometry measurements, the median fluorescence 
intensity of the dyes staining the CD3 receptors remained constant, and so did the FRET 
efficiency over time. Comparing the data from those two different setups, we could 
conclude that the CD3 coreceptor is constantly degraded, but a remaining portion can be 
found in homoclusters on cell surface or even in intracellular vesicles. Comparing those data 
with the lipid raft dissolved experiment, the FRET flow cytometry assay does not only 
provide spatial information, but we could also detect the spatial dynamic changes of CD3 
molecule arrangement on cell over time in their lipid rafts. At the same time, the CD3 
receptors are also newly transcribed and expressed on the cell surface. We could conclude 
this from the post-activation staining data, as here the overall fluorescence intensity for CD3 
remained constant. 
Taking together this data and previously described results (compare Finetti et al., 2009102), 
we developed the following model for the dynamic rearrangement of the CD3 receptor 
during T cell activation: 
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Figure 34: Model for dynamic rearrangement of the CD3 coreceptor on lipid rafts during T cell activation. The CD3 
microclusters are recycled to the immunological synapse and partly degraded during this process. In the meantime, new 
CD3 receptors are transcribed and transported to the cell surface. 
 
Before T cell activation, the CD3 receptors are equally distributed over the cell surface in 
their lipid rafts (step I, Figure 34: Model for dynamic rearrangement of the CD3 coreceptor on lipid 
rafts during T cell activation.). Immediately after the T cell becomes activated by the APC, CD3 
microclusters are formed via lipid rafts, bringing the receptors into close proximal distance 
(step II). As the immunological synapse is further established and also during synapse 
maintenance, the CD3 receptor clusters are constantly recycled in a polarized manner to the 
site of the IS, either on the cell membrane via lateral reorganization and also via intracellular 
endosomal vesicles (step III). Some of those CD3 molecules are also degraded in endosomal 
compartments during this process. However, at the same time, new CD3 receptor molecules 
are transcribed and transported to the cell surface. 
Further follow up experiments could support our model of the CD3 receptor recycling via 
intracellular vesicles. For example, the endosomal uptake could be inhibited by blocking 
substances such as dynasore103. Measuring the FRET efficiency over a longer period of time 
should lead to more constant values and also unchanged fluorescence intensities. Moreover, 
comparing the FRET efficiency results to confocal images or image stream instrument data 
might prove the spatial reorganization that we can measure in the FRET assay. In addition, 
comparing the FRET efficiency for the dynamic changes of lipid raft proteins versus non-lipid 
raft protein after T cell stimulation might reveal the dependency of the cell’s structural 
organization on lipid rafts. 
 
Discussion 
 
70 
 
6.4 Immune checkpoint inhibition 
We did not only use the FRET assay to detect the activation of T lymphocytes. We also 
wanted to study the structural rearrangements that are required to suppress the immune 
response. It had previously been described that the ligation of the PD-1 receptor to its 
ligands PD-L1 and PD-L2 on the antigen presenting cell is successfully terminating the 
immune response of the T cell104. It had also been discovered that during this process 
structural rearrangements are taking place on the cell surface, bringing the PD-1 receptor 
into close spatial distance to the CD3 coreceptor68. This structural rearrangement is required 
to terminate the immune response. However, usually PD-1 is expressed at a very low level. 
For that reason, we stimulated the PBMCs from whole blood with SEB for a long period of 
time (up to 4 days), as here the PD-1 ligand can be expressed in the APCs that are present in 
the PBMC. We measured the increase in median fluorescence intensity of PD-1. Only after T 
cell stimulation, but not for non-activated T cells both the fluorescence intensity and the 
number of PD-1 positive T cells increased. Therefore, we decided that SEB is also suitable for 
our experiments to trigger PD-1 expression for later FRET assays. 
Furthermore, we screened several tumor cell lines for the expression of PD-L1 and PD-L2 via 
flow cytometry. We found out that the breast cancer cell line MBA-MD-231 is the cell line 
with the highest proportion and expression level of both PD-L1 and PD-L2. For that reason, 
we used that cell line for the substitution of the autologous APCs if required in the FRET 
experiments. 
 
6.4.1 PD-1 CD3 FRET and isolated T cells 
In order to measure the clustering of PD-1 with the CD3 coreceptor, we used anti-PD-1 sFITC 
and anti CD3-VioBlue as antibodies for our FRET experiments. 
We could show that when we stimulated T cells with their autologous APCs in the form of 
isolated PBMCs from whole blood, we successfully measured an increase in FRET efficiency 
compared to no activation. When we isolated the T cells from the PBMCs using two different 
isolation protocols, no strong increase in FRET efficiency could be measured after T cell 
activation. Therefore, the antigen presenting cell and also its expressed PD-1 ligands are 
assumed to be essential to induce the structural rearrangements of PD-1 on the cell surface. 
When we co-cultured the T cells with the MDA-MB-231 cell line we could also increase the 
FRET efficiency to a great extend. However, this was only true if SEB was added as a 
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stimulating agent to the cells. Therefore, also here the T cell stimulation seemed to be 
required to enable a successful clustering of PD-1 with the CD3 receptor. The tumor cell line 
was even more adequate for the CD3 and PD-1 clustering experiment, as here the FRET 
efficiency was much higher compared to the use of autologous APCs. This might be due to 
the very high expression of both PD-L1 and PD-L2 that the MDA-MB-231 was described and 
tested to be positive for105,106.  
This FRET assay can most probably also be applied on other checkpoint inhibitors like CTLA-
4. For that reason, also for those receptors the clustering potency of this checkpoint 
inhibitor can be measured and from those results it can be derived whether the checkpoint 
inhibition is active or not. Furthermore different cell treatment protocols can be compared 
here.  
It could also be of great interest to test a CRISPR/Cas9 library on the tumor cell line that is 
used as APC via the CD3 and PD-1 clustering FRET assay. This might help to identify genes 
that are both important for the PD-L expression and to induce the PD-1 and CD3 clustering 
that is initiating the termination of the immune response. In that way, different knock-out 
variants could be identified that might rescue the anti-tumor immune response and could 
serve as a basis for the identification of new anti-tumor drugs. 
Finally, in order to test the clinical relevance of the CD3 and PD-1 clustering mechanism that 
is measured here, another interesting follow up experiment might be to repeat this test on 
tumor patient material. Here it one could test if the structural rearrangements do also have 
a clinical impact. For example, there could be a correlation between an impaired clustering 
of the CD3 and PD-1 receptors and a higher tumor prevalence due to that reason. It might 
also be worth testing if patients with a difference in CD3 and PD-1 as determined via FRET do 
show a difference in the response to checkpoint inhibitor anti-tumor therapy. If a difference 
could be found, this FRET assay could be used as a prognostic marker if or even as a test for 
which tumor therapy against which checkpoint inhibitor can be applied for one single 
patient. 
 
6.4.2 PD-1 CD3 FRET and PD-L blocking 
Next, we tested if we could inhibit the clustering of the CD3 and PD-1 receptors when we 
used antibodies that are specifically directed against PD-L1 and PD-L2. Here, we stimulated 
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PDBMCs with SEB and measured the impact of the blocking antibody on PD-1 ligand 
expression and on the FRET efficiency for CD3 PD-1 clustering. The blocking antibody had no 
impact on PD-1 expression as the median intensity of the anti-PD-1 sFITC conjugate was 
comparable for antibody treatment and untreated cells as determined via flow cytometry. 
However, we could identify a strong difference in FRET efficiency. Therefore, we could 
conclude that the blocking antibody successfully inhibits the clustering of the CD3 and PD-1 
receptor on the T cell’s surface that is required to terminate the immune response. This does 
imply that the anti-tumor response of the T cell could be restored by the application of the 
blocking antibody.  
Also for this assay, there are be different follow up experiments that might support the 
efficiency of the FRET experiment that is used here and would be worth testing for. If the 
lipid rafts of the T cells were disturbed by using either bCD, cholesterol or nystatin, it could 
be expected that also here an impact on the FRET efficiency could be observed.  The reason 
for that is that the fluorescent dyes labeling the CD3 and PD-1 receptors on the cell surface 
will not be clustered in such a close spatial distance as compared to completely functional 
lipid rafts considering the molecular impacts of the lipid raft modifying substances as it is 
described in 6.3.3. 
Furthermore, if the endosomal uptake was blocked in this experimental setup, for example 
by using chemicals like Dynasore, the FRET efficiency is supposed to remain at a high or even 
increased level over an increase of time. Here, the blockade of the endosomal uptake will 
inhibit the degradation especially of the CD3 coreceptor, but also the downregulation of the 
PD-1 receptor on the T cell’s surface. As a result, CD3 and PD-1 will either remain in close 
special distance, or the density of the two receptors might even increase as new receptors 
are transcribed and transported to the cell surface. This will increase the likelihood of energy 
being transferred between the fluorescent dyes and therefore lead to the increase in FRET 
efficiency. 
As mentioned in 2.5.1 Pharmaceutical use immune checkpoint inhibition modulators the PD-1 
directed antibody immunotherapy show a good efficiency in many different kind of tumors 
and there are constantly new tumor subtypes that are tested to respond to this therapy in 
ongoing clinical trials107-110. 
However, because of the sometime very severe side effects that can be observed under the 
PD-1 directed immunotherapy111, there is still a great unmet need for new substances that 
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are saver in their application for the patient. There is only one therapeutic antibody, 
atezolizumab (trade name: Tecentriq) that is directed against PD-L1 and has recently been 
approved by the FDA for the treatment of urothelial carcinoma112.  
This FRET assay might offer a fast and simple platform to screen for those substances7 that 
restore the T cell’s immune function. Here we can clearly differentiate if a substance inhibits 
the T cell’s immune response by measuring the structural rearrangements on the cell surface 
that are required for the inhibition of the immune response. Probably this assay might help 
to find substances that influence the checkpoint inhibition via a different mode of action, so 
that not only antibodies but also small molecules could be used as therapeutic agents. 
 
6.4.3 Downscale of the PD-1 CD3 FRET for screening purposes 
We transferred the FRET assay for measuring the interaction between CD3 and PD-1 on the 
cell surface of T lymphocytes as described previously into a smaller scale, using 0.5% of the 
cell volume that were used in the previously described PD-1 and CD3 clustering assay in a 
384-well plate format. Here, the T cells were isolated from buffy coats instead of whole 
blood in order to achieve a higher yield in total cell number per blood donor. 
We could observe that the FRET efficiency only increased if the tumor cell line was present 
compared to pure isolated T cells. As expected, the FRET efficiency was highest for SEB 
stimulation of the T cells that were co-cultured cells with the MDA-MB-231 tumor cell line, 
because here the PD-1 checkpoint inhibition is supposed to occur due to the long T cell 
activation. When we blocked the checkpoint inhibition by applying antibodies that were 
directed against PD-L1 and PD-L1, the FRET efficiency was strongly decreased again for both 
blood donors.  
Those flow cytometry FRET results could be confirmed by confocal images in which PD-1 and 
CD3 were fluorescently labeled. PD-1 expression was very dim for pure T cells, but increased 
after the T cells were co-cultered with MDA-MB-231 tumor cells. However, PD-1 and CD3 
only colocalized when those co-cultered cells were stimulated with SEB. This corresponds to 
the increase in FRET efficiency that we could also measure under this conditions. Also here, 
when the tumor cell line was treated with the blocking antibodies that are directed against 
the PD-1 ligand, the colocalization of PD-1 and CD3 strongly decreased although the 
expression level of PD-1 did not change. 
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The data that is discussed here is very consistent with the results that were obtained in the 
experiments that were performed without the downscale approach. Therefore, we could 
conclude that the downscaling of this experimental approach and also the T cell isolation 
from buffy coats instead of whole blood was successful and can be used for screening 
purposes.  
Even so, if one would detect a potential hit for a substance where the FRET efficiency was 
significantly reduced due to the clustering of PD-1 and CD3 on a T cell, the results will have 
to be handled with great care. The reason for this is that the substances that are to be 
screened might have wide-ranging impact on general cellular behavior and performance, as 
those substances might not only target the rearrangement of the PD-1 receptor directly, but 
may also impact any upstream processes in the cell that could be essential for cell survival. 
Therefore, further methods should be applied for a hit substance in order to validate that 
the checkpoint inhibition pathway is targeted specifically.  
Beyond that, to prove the functionality of this FRET screening approach for clinical drug 
discovery, an antibody that is already used in the clinical setting for the treatment of 
patients could be tested as a positive control. Until now, there is only one PD-1 checkpoint 
inhibitor antibody approved that is targeting PD-1 ligands: the anti PD-L1 antibody 
atezolizumab was approved by the FDA for the treatment of urothelial carcinoma and also 
non-small cell lung cancer in 2016112,113. This antibody might serve as a good reference to 
validate the results of a PD-1 clustering FRET screening. 
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6.5 Conclusions 
In the study presented here an automated FRET assay had been developed that allows for 
the detection of protein-protein interactions and also their dynamic changes via FRET 
efficiency calculation on a commercially available flow cytometer. 
In this study, it could shown that this FRET program is working for different applications, 
using fluorophores coupled to different monoclonal antibodies as FRET dyes. T cell activation 
could be measured via both CD3 and CD4 receptor clustering, as well as CD3 coreceptor 
homoclustering FRET. 
Furthermore, it could be demonstrated shat the increase in FRET efficiency correlated with 
the T cell activation status when the receptors began to cluster after a very short amount of 
time. Using this method, the T cell activation could be measured even faster than with the 
conventional calcium influx assay. Based on the change in FRET efficiency over a time period 
of several hours, also conclusions could be drawn on the dynamics of CD3 recycling and 
degradation processes on an activated T cell. In addition, even receptor clustering 
impairments on T cells using blood samples from patients suffering from severe immune 
deficiencies could be validated using this automated FRET assay. 
However, we were not only able to detect T cell activation, but could also measure immune 
checkpoint inhibition occurring on T cells using the automated FRET assay. Here, the 
clustering of the PD-1 receptor with the CD3 increased when the T cell was stimulated 
unspecifically via SEB, leading to an increase in FRET efficiency. This effect was further 
pronounced when a tumor cell line was used to induce checkpoint inhibition instead of an 
autologous APC. Tthe increase in FRET efficiency could be blocked for the immune 
checkpoint inhibition as determined by an inhibited FRET efficiency increase by using specific 
antibodies that are directed against the ligands of PD1. Therefore, the automated FRET assay 
can further be applied for compound screenings on pharmacologically active substances that 
inhibit tumor immune escape mechanisms. 
Apart from that, the automated FRET assay can be used to detect a wide range of molecular 
interactions on cells and is not only limited to proteins that are expressed on the cell surface. 
For that reason, this program can be applied to reveal a wide range of dynamic processes 
that regulate cell behavior and fate. 
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auf dich verlassen, und dafür bin ich dir unendlich dankbar! 
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9. Appendix  
9.1   The FRET Express Mode Script 
from expressModes import basisEasyPageManager 
from expressModes import basisEasyPage 
from expressModes import basisGating 
from expressModes import basisEasyPageTemplate 
from expressModes import em_utilities 
from expressModes import standardGating 
from expressModes import basisExpressMode 
 
import mq 
import re 
import os 
import time 
import expressModes 
 
from mq import mDebug 
 
from __main__ import App 
from __main__ import Script 
from __main__ import Config 
 
em_version = expressModes.__version__ 
em_version = '.'.join([str(elm) for elm in em_version]) 
em_name    = 'FRETexportData' 
 
DOTPLOT     = basisEasyPageTemplate.BasisEasyPlotTemplate.DOTPLOT 
DENSITYPLOT = basisEasyPageTemplate.BasisEasyPlotTemplate.DENSITYPLOT 
HISTOGRAM   = basisEasyPageTemplate.BasisEasyPlotTemplate.HISTOGRAM 
SCRIPTTEXT  = basisEasyPageTemplate.BasisEasyPlotTemplate.SCRIPTTEXT 
EDITVIEWOFF = basisEasyPageTemplate.BasisEasyPlotTemplate.EDITVIEWOFF 
HIDENONE    = basisEasyPageTemplate.BasisEasyPlotTemplate.HIDENONE 
HIDEOTHER   = basisEasyPageTemplate.BasisEasyPlotTemplate.HIDEOTHER 
HIDEALL     = basisEasyPageTemplate.BasisEasyPlotTemplate.HIDEALL 
 
#default settings for processing FRET application 
 
Annotations = { 
    'VioBlue'  : 'Donor-VioBlue', 
    'VioGreen' : 'FRET-VioGeen', 
    'FITC'     : 'Acceptor-FITC', 
    'PE'       : 'PE', 
    'PI'       : 'PI', 
    'APC'      : 'APC' 
} 
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#colors 
black = "#000000" 
purple = "#8904B1" 
darkblue = "#084B8A" 
lightblue = "#00BFFF" 
red = "#FF4000" 
green = "#04B404" 
grey = "#6E6E6E" 
 
def defaultSettings( ): 
    return { 
        'PerformSampleMixing' : "Off", #changed from False to off between EM versions 
        'UptakeVolume'        : 100, 
        'SampleVolume'        : 250, 
        'Mode'                : 'Standard', 
        'EventLimited'        : False, 
        'EventLimit'          : 10000, 
        'FlowRate'            : 'Medium', 
        'AutoFlowRate'        : False, 
        'Reagents'            : (), 
        'Annotations'         : em_utilities.getAnnotations( Annotations ) 
    } 
 
#-------------------------------------------------- 
# Global Variables for this modules 
#-------------------------------------------------- 
channel_list = ( 'FSC', 'SSC', 'VioBlue', 'VioGreen', 'FITC' ) 
 
#-------------------------------------------------- 
# default Groups 
#-------------------------------------------------- 
def defaultGroups( ): 
    return { 
            1 : 'Blank', 
            2 : 'VioBlue_Donor', 
            3 : 'FITC_Acceptor', 
            4 : 'VioGreen_FRET', 
            #5 : 'APC_Donor', 
            #6 : 'Cy5_Acceptor', 
            #7 : 'APC-Cy5_FRET', 
            #8 : 'FITC_Donor', 
            #9 : 'mCherry_Acceptor', 
            #10: 'PI_FRET' 
    } 
 
#------------------------------------------------------- 
# Acquisition Page 
#------------------------------------------------------- 
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class FRETAcquisitionPage( basisEasyPage.BaseEasyPage ): 
 
    def __init__( self, MainFrame ): 
 
        basisEasyPage.BaseEasyPage.__init__( self, MainFrame, "FRETAcquisitionPage" ) 
        self._setInfo( "FRET acquisition" ) 
        SampleName = "live" 
 
        Sample = App.sample( SampleName ) 
        Sample.removeSubPopulations() 
 
        channels_A = em_utilities.get_channelNames( "A", channel_list, Sample ) 
        channels_H = em_utilities.get_channelNames( "H", channel_list, Sample ) 
 
        Plot1 = [ DOTPLOT,   SampleName, channels_A['FSC'],      channels_A['SSC'],     { 'edit' : 
False, 'populations' : (SampleName,) }, HIDENONE ] 
        Plot2 = [ DOTPLOT,   SampleName, channels_A['FSC'],      channels_H['FSC'],     { 'edit' : 
False, 'populations' : (SampleName,) }, HIDEOTHER ] 
        Plot3 = [ DOTPLOT,   SampleName, channels_A['VioGreen'], channels_A['VioBlue'], 
{ 'edit' : False, 'populations' : (SampleName,) }, HIDEOTHER ] 
        Plot4 = [ DOTPLOT,   SampleName, channels_A['VioGreen'], channels_A['FITC'],    { 'edit' : 
False, 'populations' : (SampleName,) }, HIDEOTHER ] 
        PageDesc = [ Plot1, Plot2, Plot3, Plot4 ] 
 
        Plots = basisEasyPageTemplate.BasisEasyPlotTemplate( self ) 
        Plots._drawPlots( PageDesc, "view4" ) 
 
        for plot in self.plots(): 
            plot.setTableRegionFuncs( ["Path","%-#"] ) 
 
        self._mainFrame( ).setSave( Config.SB_Analysis ) 
 
#------------------------------------------------------- 
# Analyse Pages 
# 1: Group-Member specific Page 
# 2: Script-Text only 
# 3: Final Result 
# 4: Page for data from mqd-Writer => calculated FRETefficiency for all events 
#------------------------------------------------------- 
class FRETAnalysePage2( basisEasyPage.BaseEasyPage ): 
 
    def __init__( self, MainFrame, SampleName, alpha, fractions, fractionName ): 
        basisEasyPage.BaseEasyPage.__init__( self, MainFrame, "FRETAnalysePage2" ) 
        self.fractions = fractions 
        self.fractionName = fractionName 
        self.alpha = alpha 
        sample = App.sample( SampleName ) 
        self.channels_A = em_utilities.get_channelNames( "A", channel_list, sample ) 
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        # self.channels_H = em_utilities.get_channelNames( "H", channel_list, sample ) 
        self.__drawPlots( SampleName ) 
 
    def __drawPlots( self, SampleName ): 
 
        # legend = "$$setvar( 'FRET', textblocks.FretCalculation.Fret(sample, 
'%s', %f ) )$$" %( em_version, self.alpha ) 
        # legend += " $$var['FRET'].getIntensities()$$ <p></p>" 
        # legend += " $$var['FRET'].getBackGround()$$ <p></p>" 
        # legend += " $$var['FRET'].getCrosstalk()$$ <p></p>" 
        # legend += " $$var['FRET'].getResults()$$" 
 
        legend = createIntensitiesTable( SampleName, self.fractions, self.channels_A ) 
        legend += "<p></p>" 
        legend += createBackGroundTable( SampleName, self.fractions, self.channels_A ) 
        legend += "<p></p><p></p><BR><BR>" 
        legend += createCrosstalkTable( SampleName, self.fractions, self.channels_A ) 
        legend += "<p></p>" 
        legend += createResultsTable( SampleName, self.fractions, self.alpha, self.channels_A ) 
 
        PageDesc = [ [ SCRIPTTEXT, SampleName, legend, (), EDITVIEWOFF ] ] 
 
        Plots = basisEasyPageTemplate.BasisEasyPlotTemplate( self ) 
        Plots._drawPlots( PageDesc, "view1" ) 
 
        for plot in self.plots(): 
            plot.setTableRegionFuncs( ["Path","%-#"] ) 
 
        self._mainFrame( ).setSave( Config.SB_Analysis ) 
 
class FRETAnalysePage3( basisEasyPage.BaseEasyPage ): 
 
    def __init__( self, MainFrame, SampleName, alpha, fractions, fractionName ): 
        basisEasyPage.BaseEasyPage.__init__( self, MainFrame, "FRETAnalysePage3" ) 
        # self.mySample = App.sample(SampleName) 
        self.fractions = fractions 
        self.fractionName = fractionName 
        self.alpha = alpha 
        sample = App.sample( SampleName ) 
        self.channels_A = em_utilities.get_channelNames( "A", channel_list, sample ) 
        self.channels_H = em_utilities.get_channelNames( "H", channel_list, sample ) 
 
        self.__drawPlots( SampleName ) 
 
    def __drawPlots(self, SampleName ): 
 
        fraction = self.fractions["VioGreen_FRET"] 
        G0_FR = fraction['GroupGateName'].name() #Ohne Gate 
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        G2_FR = fraction['ScatterGate'].name()   #Target Population 
        G3_FR = fraction['SingletGate'].name()    #Singlet Gate 
        G4_FR = fraction['Donor'].name() 
        G5_FR = fraction['Acceptor'].name() 
 
 
        # legend = "$$setvar( 'FRET', textblocks.FretCalculation.Fret(sample, 
'%s', %f ) )$$" %( em_version, self.alpha ) 
        # legend += "$$var['FRET'].getIntensities()$$ <p></p>" 
        # legend += "$$var['FRET'].getResults()$$" 
 
        legend = createIntensitiesTable( SampleName, self.fractions, self.channels_A ) 
        legend += "<p></p>" 
        legend += createResultsTable( SampleName, self.fractions, self.alpha, self.channels_A ) 
 
        Plot1 = [ DOTPLOT, G0_FR, self.channels_A['FSC'],       self.channels_A['SSC'],       { 'edit' : 
False, 'populations' : (G0_FR,G2_FR) }, HIDENONE ] 
        Plot2 = [ DOTPLOT, G2_FR, self.channels_A['FSC'],       self.channels_H['FSC'],       { 'edit' : 
False, 'populations' : (G2_FR,G3_FR) }, HIDENONE ] 
        Plot3 = [ DOTPLOT, G3_FR, self.channels_A['VioBlue'],   self.channels_A['VioGreen'],  
{ 'edit' : False, 'populations' : (G3_FR,) }, HIDENONE ] 
        Plot4 = [ DOTPLOT, G3_FR, self.channels_A['FITC'],      self.channels_A['VioGreen'],  
{ 'edit' : False, 'populations' : (G3_FR,) }, HIDENONE ] 
 
        Table = [ SCRIPTTEXT, SampleName, legend, (), EDITVIEWOFF ] 
 
        PageDesc = [ Plot1, Plot2, Plot3, Table, Plot4 ] 
 
        Plots = basisEasyPageTemplate.BasisEasyPlotTemplate( self ) 
        Plots._drawPlots( PageDesc, "view6b" ) 
 
        for plot in self.plots(): 
            plot.setTableRegionFuncs( ["Path","%-#"] ) 
 
        self._mainFrame( ).setSave( Config.SB_Analysis ) 
 
class FRETAnalysePage1( basisEasyPage.BaseEasyPage ): 
 
    def __init__( self, MainFrame, SampleName, alpha, fractions, fractionName ): 
        basisEasyPage.BaseEasyPage.__init__( self, MainFrame, "FRETAnalysePage1" ) 
        Sample = App.sample(SampleName) 
        self.fractions = fractions 
        self.fractionName = fractionName 
        self.alpha = alpha 
        self.channels_A = em_utilities.get_channelNames( "A", channel_list, Sample ) 
        self.channels_H = em_utilities.get_channelNames( "H", channel_list, Sample ) 
 
        self.__drawPlots( SampleName ) 
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    def __drawPlots(self, SampleName): 
 
        fraction = self.fractions[self.fractionName] 
        G0 = fraction['GroupGateName'].name() #Ohne Gate 
        G2 = fraction['ScatterGate'].name()   #Target Population 
        G3 = fraction['SingletGate'].name()    #Singlet Gate 
        G4 = fraction['Donor'].name() 
        G5 = fraction['Acceptor'].name() 
        G6 = fraction['FRET'].name() 
 
        # legend_M = "$$textblocks.FretCalculation.Fret(sample, 
'%s', %f ).getMedians( '%s' )$$" %( em_version, self.alpha, self.fractionName ) 
        legend_M = createMedianTable( SampleName, self.fractions[self.fractionName], 
self.channels_A ) 
 
        Plot1 = [ DOTPLOT,   G0, self.channels_A['FSC'],      self.channels_A['SSC'],      { 'edit' : 
False, 'populations' : (G0,G2) }, HIDENONE ] 
        Plot2 = [ DOTPLOT,   G0, self.channels_A['FSC'],      self.channels_H['FSC'],      { 'edit' : 
False, 'populations' : (G2,) }, HIDENONE ] 
        Plot3 = [ DOTPLOT,   G3, self.channels_A['VioBlue'],  self.channels_A['VioGreen'], { 'edit' : 
False, 'populations' : (G3,) }, HIDENONE ] 
        Plot4 = [ DOTPLOT,   G3, self.channels_A['FITC'],     self.channels_A['VioGreen'], { 'edit' : 
False, 'populations' : (G3,) }, HIDENONE ] 
        Plot5 = [ HISTOGRAM, G4, self.channels_A['VioBlue'],  None,                        { 'edit' : False, 
'populations' : (G4,) }, HIDEOTHER ] 
        Plot6 = [ HISTOGRAM, G5, self.channels_A['FITC'],     None,                        { 'edit' : False, 
'populations' : (G5,) }, HIDEOTHER ] 
        Plot7 = [ HISTOGRAM, G6, self.channels_A['VioGreen'], None,                        { 'edit' : False, 
'populations' : (G6,) }, HIDEOTHER ] 
 
        ScriptTextTable = [ SCRIPTTEXT, SampleName, legend_M, (), EDITVIEWOFF ] 
 
        PageDesc = [ Plot1, Plot2, Plot3, Plot4, Plot5, Plot6, ScriptTextTable, Plot7 ] 
 
        Plots = basisEasyPageTemplate.BasisEasyPlotTemplate( self ) 
        Plots._drawPlots( PageDesc, "view8b" ) 
 
        Hist1 = self.plots()[4] 
        Hist2 = self.plots()[5] 
        Hist3 = self.plots()[6] 
        Hist1.setTableFeatures([self.channels_A['VioBlue']]) 
        Hist1.setTableFeatureFuncs(['Median']) 
        Hist2.setTableFeatures([self.channels_A['FITC']]) 
        Hist2.setTableFeatureFuncs(['Median']) 
        Hist3.setTableFeatures([self.channels_A['VioGreen']]) 
        Hist3.setTableFeatureFuncs(['Median']) 
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        for plot in self.plots(): 
            plot.setTableRegionFuncs( ["Path","%-#"] ) 
 
        self._mainFrame( ).setSave( Config.SB_Analysis ) 
 
class FRETAnalysePage4( basisEasyPage.BaseEasyPage ): 
 
    def __init__( self, MainFrame, SampleName, alpha, fractions, fractionName ): 
        basisEasyPage.BaseEasyPage.__init__( self, MainFrame, "FRETAnalysePage4" ) 
        self.fraction = fractions[fractionName] 
        self.__drawPlots() 
 
    def __drawPlots(self): 
 
        G1 = self.fraction['Double positives'].name() 
        G2 = self.fraction['Target Population'].name() 
        G3 = self.fraction['Singlet Population'].name() 
 
        Plot1 = [ HISTOGRAM,   G3, 'FRET',        None,    EDITVIEWOFF, HIDENONE ] 
        Plot2 = [ DENSITYPLOT, G1, 'FSC-A',       'SSC-A', EDITVIEWOFF, HIDENONE ] 
        Plot3 = [ DOTPLOT,     G2, 'FSC-A',       'FSC-H', EDITVIEWOFF, HIDENONE ] 
        Plot4 = [ HISTOGRAM,   G3, 'Donor',       None,    EDITVIEWOFF, HIDEOTHER ] 
        Plot5 = [ HISTOGRAM,   G3, 'Acceptor',    None,    EDITVIEWOFF, HIDEOTHER ] 
        Plot6 = [ HISTOGRAM,   G3, 'FRETchannel', None,    EDITVIEWOFF, HIDEOTHER ] 
 
        PageDesc = [ Plot1, Plot2, Plot3, Plot4, Plot5, Plot6 ] 
 
        Plots = basisEasyPageTemplate.BasisEasyPlotTemplate( self ) 
        Plots._drawPlots( PageDesc, "view6a" ) 
 
        for plot in self.plots(): 
            plot.setTableRegionFuncs( ["Path","%-#"] ) 
 
        self._mainFrame( ).setSave( Config.SB_Analysis ) 
         
         
class FRETAnalysePageFRETonly( basisEasyPage.BaseEasyPage ): 
 
    def __init__( self, MainFrame, SampleName, alpha, fractions, fractionName ): 
        basisEasyPage.BaseEasyPage.__init__( self, MainFrame, "FRETAnalysePage3" ) 
        # self.mySample = App.sample(SampleName) 
        self.fractions = fractions 
        self.fractionName = fractionName 
        self.alpha = alpha 
        sample = App.sample( SampleName ) 
        self.channels_A = em_utilities.get_channelNames( "A", channel_list, sample ) 
        self.channels_H = em_utilities.get_channelNames( "H", channel_list, sample ) 
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        self.__drawPlots( SampleName ) 
 
    def __drawPlots(self, SampleName ): 
 
        fraction = self.fractions["VioGreen_FRET"] 
        G0_FR = fraction['GroupGateName'].name() #Ohne Gate 
        G2_FR = fraction['ScatterGate'].name()   #Target Population 
        G3_FR = fraction['SingletGate'].name()    #Singlet Gate 
        G4_FR = fraction['Donor'].name() 
        G5_FR = fraction['Acceptor'].name() 
 
        legend = createIntensitiesTableFRET( SampleName, self.fractions, self.channels_A ) 
        legend += "<p></p>" 
        legend += createResultsTableFRET( SampleName, self.fractions, self.alpha, 
self.channels_A ) 
        legend += createExportFRET( SampleName, self.fractions, self.alpha, self.channels_A ) 
 
        Plot1 = [ DOTPLOT, G0_FR, self.channels_A['FSC'],       self.channels_A['SSC'],       { 'edit' : 
False, 'populations' : (G0_FR,G2_FR) }, HIDENONE ] 
        Plot2 = [ DOTPLOT, G2_FR, self.channels_A['FSC'],       self.channels_H['FSC'],       { 'edit' : 
False, 'populations' : (G2_FR,G3_FR) }, HIDENONE ] 
        Plot3 = [ DOTPLOT, G3_FR, self.channels_A['VioBlue'],   self.channels_A['VioGreen'],  
{ 'edit' : False, 'populations' : (G3_FR,) }, HIDENONE ] 
        Plot4 = [ DOTPLOT, G3_FR, self.channels_A['FITC'],      self.channels_A['VioGreen'],  
{ 'edit' : False, 'populations' : (G3_FR,) }, HIDENONE ] 
 
        Table = [ SCRIPTTEXT, SampleName, legend, (), EDITVIEWOFF ] 
 
        PageDesc = [ Plot1, Plot2, Plot3, Table, Plot4 ] 
 
        Plots = basisEasyPageTemplate.BasisEasyPlotTemplate( self ) 
        Plots._drawPlots( PageDesc, "view6b" ) 
 
        for plot in self.plots(): 
            plot.setTableRegionFuncs( ["Path","%-#"] ) 
 
        self._mainFrame( ).setSave( Config.SB_Analysis ) 
 
###########################################################################
#################################### 
 
###########################################################################
#################################### 
#------------------------------------------------------- 
# Main analysis algorithmic 
#------------------------------------------------------- 
def __analyseFRET( SampleName, pv ): 
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    Sample = App.sample( SampleName ) 
    Sample.removeSubPopulations() 
    Sample.createGroupRegions() 
    Fractions = __retrieveFractions( SampleName ) 
    channels_A = em_utilities.get_channelNames( 'A', channel_list, Sample ) 
    channels_H = em_utilities.get_channelNames( 'H', channel_list, Sample ) 
 
    if "VioGreen_FRET" not in Fractions: 
        return False,{} 
 
    if "Blank" in Fractions: 
        
        FRET_Fraction = Fractions["VioGreen_FRET"] 
        Blank_Fraction = Fractions["Blank"] 
        Donor_Fraction = Fractions["VioBlue_Donor"] 
        Acceptor_Fraction = Fractions ["FITC_Acceptor"] 
        print 'GroupgateName', FRET_Fraction['GroupGateName'] 
     
        #----------------------------------------------------- 
        # first run:pre-gating on target population 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START pre-gating1 on target population.....' ) 
     
        Range_X = GetRange( FRET_Fraction['GroupGateName'], channels_A['VioBlue'], -1.25, 
minPeak=64 ) 
        Range_Y = GetRange( FRET_Fraction['GroupGateName'], channels_A['FITC'], -1.25, 
minPeak=64 ) 
     
        coords_Pre = basisGating._calculateCoordinates( Range_X, Range_Y ) 
     
        preGate = standardGating.applyPolygonGate( FRET_Fraction['GroupGateName'], 
coords_Pre, 
                                                   channels_A['VioBlue'], channels_A['FITC'], grey, "PreGate1" ) 
        FRET_Fraction['PreGate'] = preGate 
     
        pv.setProgress(1) 
     
        #------------------------------------------------------------------------------ 
        #Gating on Target Population 
        #----------------------------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on target population.....' ) 
     
        scatterGate = CreateEllipseGate( FRET_Fraction['PreGate'], 
FRET_Fraction['GroupGateName'], 
                                    channels_A['FSC'], channels_A['SSC'], purple, 'ScatterGate' ) 
     
     
        if scatterGate == None: 
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            raise em_utilities.AnalysisException( "Failed to create ScatterGate", Fractions ) 
     
        FRET_Fraction['ScatterGate'] = scatterGate 
        copyGateToOtherFractions( Fractions, "VioGreen_FRET", scatterGate, "ScatterGate", 
'GroupGateName' ) 
     
        pv.setProgress(2) 
     
        #----------------------------------------------------- 
        # Gating on SINGLETS 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on singlets.....' ) 
     
        singletGate = standardGating.calculateSingletGate( FRET_Fraction['ScatterGate'], 
channels_A['FSC'], 
                                                           channels_H['FSC'], 'SingletGate', darkblue ) 
        if singletGate == None: 
            raise em_utilities.AnalysisException( "Failed to create singletGate", Fractions ) 
     
        FRET_Fraction['SingletGate'] = singletGate 
     
        copyGateToOtherFractions( Fractions, "VioGreen_FRET", singletGate, "SingletGate", 
"ScatterGate" ) 
     
        #----------------------------------------------------- 
        # Gating on DONOR: S1 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on donor positive population.....' ) 
     
        DonorRegion = CreateSGate( Donor_Fraction['SingletGate'], channels_A['VioBlue'], 
channels_A['VioGreen'], red, "S1") 
        Donor_Fraction['Donor'] = DonorRegion 
     
        FRETRegion = CreateSGate( FRET_Fraction['SingletGate'], channels_A['VioBlue'], 
channels_A['VioGreen'], red, "S1") 
        FRET_Fraction['Donor'] = FRETRegion 
     
        BlankRegion = CreateWholeRange( Blank_Fraction['SingletGate'], red, 
channels_A['VioBlue'] ) 
        Blank_Fraction['Donor']= BlankRegion 
     
        AcceptorRegion = CreateWholeRange( Acceptor_Fraction['SingletGate'], red, 
channels_A['VioBlue'] ) 
        Acceptor_Fraction['Donor'] = AcceptorRegion 
     
        pv.setProgress(3) 
     
        #----------------------------------------------------- 
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        # Gating on ACCEPTOR 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on acceptor positive population.....' ) 
     
        BlankRegion = CreateWholeRange( Blank_Fraction['SingletGate'], lightblue, 
channels_A['FITC'] ) 
        Blank_Fraction['Acceptor'] = BlankRegion 
     
        DonorRegion = CreateWholeRange( Donor_Fraction['SingletGate'], lightblue, 
channels_A['FITC'] ) 
        Donor_Fraction['Acceptor'] = DonorRegion 
     
        AcceptorRegion = CreateSGate( Acceptor_Fraction['SingletGate'], channels_A['FITC'], 
channels_A['VioGreen'], 
                                      lightblue, "S2") 
        Acceptor_Fraction['Acceptor'] = AcceptorRegion 
     
        FRETRegion = CreateSGate( FRET_Fraction['SingletGate'], channels_A['FITC'], 
channels_A['VioGreen'], 
                                  lightblue, "S2") 
        FRET_Fraction['Acceptor'] = FRETRegion 
     
        pv.setProgress(4) 
     
        #----------------------------------------------------- 
        # Gating on FRET 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START Gating on FRET positive population.....' ) 
     
        BlankRegion = CreateWholeRange( Blank_Fraction['SingletGate'], green, 
channels_A['VioGreen'] ) 
        Blank_Fraction['FRET'] = BlankRegion 
     
        DonorRegion = CreateWholeRange( Donor_Fraction['Donor'], green, 
channels_A['VioGreen'] ) 
        Donor_Fraction['FRET'] = DonorRegion 
     
        AcceptorRegion = CreateWholeRange( Acceptor_Fraction['SingletGate'], green, 
channels_A['VioGreen'] ) 
        Acceptor_Fraction['FRET'] = AcceptorRegion 
     
        FRETRegion = CreateWholeRange( FRET_Fraction['Donor'], green, 
channels_A['VioGreen'] ) 
        FRET_Fraction['FRET'] = FRETRegion 
     
        pv.setProgress(5) 
     
        return True,Fractions 
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    else: 
        FRET_Fraction = Fractions["VioGreen_FRET"] 
        print 'GroupgateName', FRET_Fraction['GroupGateName'] 
        #----------------------------------------------------- 
        # first run:pre-gating on target population 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START pre-gating1 on target population.....' ) 
     
        Range_X = GetRange( FRET_Fraction['GroupGateName'], channels_A['VioBlue'], -1.25, 
minPeak=64 ) 
        Range_Y = GetRange( FRET_Fraction['GroupGateName'], channels_A['FITC'], -1.25, 
minPeak=64 ) 
     
        coords_Pre = basisGating._calculateCoordinates( Range_X, Range_Y ) 
     
        preGate = standardGating.applyPolygonGate( FRET_Fraction['GroupGateName'], 
coords_Pre, 
                                                   channels_A['VioBlue'], channels_A['FITC'], grey, "PreGate1" ) 
        FRET_Fraction['PreGate'] = preGate 
     
        pv.setProgress(1) 
     
        #------------------------------------------------------------------------------ 
        #Gating on Target Population 
        #----------------------------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on target population.....' ) 
     
        scatterGate = CreateEllipseGate( FRET_Fraction['PreGate'], 
FRET_Fraction['GroupGateName'], 
                                    channels_A['FSC'], channels_A['SSC'], purple, 'ScatterGate' ) 
     
        if scatterGate == None: 
            raise em_utilities.AnalysisException( "Failed to create ScatterGate", Fractions ) 
     
        FRET_Fraction['ScatterGate'] = scatterGate 
        copyGateToOtherFractions( Fractions, "VioGreen_FRET", scatterGate, "ScatterGate", 
'GroupGateName' ) 
     
        pv.setProgress(2) 
     
        #----------------------------------------------------- 
        # Gating on SINGLETS 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on singlets.....' ) 
     
        singletGate = standardGating.calculateSingletGate( FRET_Fraction['ScatterGate'], 
channels_A['FSC'], 
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                                                           channels_H['FSC'], 'SingletGate', darkblue ) 
        if singletGate == None: 
            raise em_utilities.AnalysisException( "Failed to create singletGate", Fractions ) 
     
        FRET_Fraction['SingletGate'] = singletGate 
     
        copyGateToOtherFractions( Fractions, "VioGreen_FRET", singletGate, "SingletGate", 
"ScatterGate" ) 
     
        #----------------------------------------------------- 
        # Gating on DONOR: S1 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on donor positive population.....' ) 
     
     
        FRETRegion = CreateSGate( FRET_Fraction['SingletGate'], channels_A['VioBlue'], 
channels_A['VioGreen'], red, "S1") 
        FRET_Fraction['Donor'] = FRETRegion 
     
        pv.setProgress(3) 
     
        #----------------------------------------------------- 
        # Gating on ACCEPTOR 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START gating on acceptor positive population.....' ) 
     
        FRETRegion = CreateSGate( FRET_Fraction['SingletGate'], channels_A['FITC'], 
channels_A['VioGreen'], 
                                  lightblue, "S2") 
        FRET_Fraction['Acceptor'] = FRETRegion 
     
        pv.setProgress(4) 
     
        #----------------------------------------------------- 
        # Gating on FRET 
        #----------------------------------------------------- 
        mDebug( 'log', 0, 'START Gating on FRET positive population.....' ) 
     
        FRETRegion = CreateWholeRange( FRET_Fraction['Donor'], green, 
channels_A['VioGreen'] ) 
        FRET_Fraction['FRET'] = FRETRegion 
        pv.setProgress(5) 
 
        return True,Fractions 
         
 
def __analyseFRET2( SampleName, pv, Fractions ): 
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    Sample = App.sample( SampleName ) 
    CoordsPreGate = Fractions['VioGreen_FRET']['PreGate'].points() 
    CoordsSingletGate = Fractions['VioGreen_FRET']['SingletGate'].points() 
 
    FRET_Fraction = {} 
    gateName = "Double positives" 
    Pop1 = standardGating.applyPolygonGate( Sample, CoordsPreGate, 'Donor', 'Acceptor', 
grey, gateName ) 
    FRET_Fraction[gateName] = Pop1 
 
    gateName = "Target Population" 
    Pop2 = CreateEllipseGate( Sample, Pop1, 'FSC-A', 'SSC-A', purple, gateName ) 
 
    if Pop2==None: 
        raise Exception( 'Failed to create TargetPopulation' ) 
 
    FRET_Fraction[gateName] = Pop2 
 
    gateName = "Singlet Population" 
    Pop3 = standardGating.applyPolygonGate( Pop2, CoordsSingletGate, 'FSC-A', 'FSC-H', 
darkblue, gateName ) 
    FRET_Fraction[gateName] = Pop3 
 
    pv.setProgress( 8 ) 
 
    Fractions['FRET'] = FRET_Fraction 
 
    return Fractions 
 
###########################################################################
############################ 
#------------------------------------------------------- 
# Gating-Helper Functions 
#------------------------------------------------------- 
def __retrieveFractions( sampleName ): 
    allGroups = defaultGroups() 
    mySample = App.sample( sampleName) 
    groupInfo = mySample.groupInfo() 
    print 'Groupinfo:', groupInfo 
    # mDebug( 'log', 0, "groupInfo:",groupInfo ) 
    fractions = {} 
     
    print 'Bin hie kurz vor schleife'         
    try: 
        grouplist = dict([(str(v), k) for k, v in groupInfo.items()]) 
        print grouplist 
        groupstring = ''.join(grouplist) 
        if True: 
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            if groupstring.find('Blank') >= 1: 
                print 'TRUE', groupstring 
                for fk,fv in groupInfo.items(): 
                    # mDebug( 'log', 0, "__retrieveFractions:", fk,fv ) 
                    GroupNameFromSample =fv[1] 
                    for groupName in allGroups.values(): 
                        if GroupNameFromSample== groupName: 
                            if GroupNameFromSample in fractions: 
                                pass 
                            groupGateName = sampleName + '\\G'+str(fk) 
                            fractions[ GroupNameFromSample ] = { 'GroupNum' : fk, 'GroupGateName' : 
App.sample(groupGateName) } 
    except: 
        fractions[ 'VioGreen_FRET' ] = { 'GroupNum' : 1, 'GroupGateName' : mySample }      
        print 'bin in else schleife' 
         
    print 'Bin wieder raus', fractions 
 
    return fractions 
     
def _applyHistogramGate( ParentPop, Range, Channel, color ): 
    # sample = App.sample( ParentPop ) 
    # print "applyHistogramGate:", Channel, Range 
    region = ParentPop.createMarker( Channel,(int(Range[0]), int(256)), (int(Range[1]), 
int(256)) ) 
    region.setRegionColor( color ) 
    return region 
 
def copyGateToOtherFractions( fractions, targetFraction, targetSample, name, basename ): 
    #------------------------------------------ 
    # copy region to other fractions 
    #------------------------------------------ 
    for key,fraction in fractions.iteritems(): 
        if key == targetFraction: 
            continue 
        try: 
            copyGateToFraction( fraction, targetSample, name, basename ) 
        except: 
            raise em_utilities.AnalysisException( "Failed to link gate to %s" % (key), fractions ) 
 
def copyGateToFraction( fraction, targetSample, name, basename ): 
    #------------------------------------------ 
    # copy region to given fraction 
    #------------------------------------------ 
    BasePopulation = fraction[basename] 
    #mDebug( 'log', 0, 'letzter Name von ', key, BaseRegionName ) 
    #mDebug( 'log', 0, basename, BasePopulation.name() ) 
    success = BasePopulation.linkToRegion( targetSample.region() ) 
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    if not success: 
        raise Exception( "Failed to link gate to" ) 
 
    NewRegionName = BasePopulation.subPopulations( False )[-1] 
    #mDebug( 'log', 0, NewRegionName ) 
    fraction[name] = App.sample( NewRegionName ) 
 
def getPeakWithSDCorrection(Histogram, factor): 
    Peak = Histogram.mean + Histogram.SD * factor 
    return Peak 
 
def CreateHistGate( ParentPop, color, Channel ): 
    Range = GetSplit( ParentPop, Channel, -1.25, minPeak=64 ) 
    region = _applyHistogramGate( ParentPop, Range, Channel, color ) 
    return region 
 
def GetRange( ParentPop, Channel, factor, minPeak=False ): 
    print "GetRange called", Channel, factor 
    Histogram = standardGating.PrepareHistogram( ParentPop, Channel ) 
    Histogram.calcStat() 
 
    Peak = getPeakWithSDCorrection( Histogram, factor ) 
    Range = ( 2*Peak, 512 ) 
 
    return Range 
 
def GetSplit( ParentPop, Channel, factor, minPeak=False ): 
    Histogram = standardGating.PrepareHistogram( ParentPop, Channel ) 
    Histogram.calcStat() 
    #Peak = 2 * getPeakWithSDCorrection( Histogram, factor ) 
    #Peak = 2* standardGating.CalculateSplit( Histogram ) 
    #print PEAK, 'Peak' 
 
    minima = Histogram._getLocalMinima() 
    if len(minima)>2 : 
        Peak = Histogram._getOptimalSplit(3.5) 
        if Peak != None: 
            Peak = Peak[1] 
            print Channel, ': OPTIMAL SPLIT' 
 
        else: 
            Peak = Histogram._getPossibleSplit(0, 0.5 ) 
            print Channel, ': POSSIBLE SPLIT' 
 
        #~ if Peak > 240: 
            #~ Peak = 2 * getPeakWithSDCorrection( Histogram, factor ) 
            #~ print 'PEAK WITH SD CORRECTION' 
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    else: 
        print Channel, ": No BiModal distribution!", factor 
        Peak = getPeakWithSDCorrection( Histogram, factor ) 
 
    Range = ( 2*Peak, 512 ) 
 
    return Range 
 
def CreateWholeRange( ParentPop, color, Channel ): 
    # print "CreateWholeRange:", ParentPop, color, Channel 
    Range = (1, 510) 
    region = _applyHistogramGate( ParentPop, Range, Channel, color ) 
    return region 
 
def CreateSGate( ParentPop, Channel1, Channel2, Color, Name="" ): 
    region = CreateEllipseGate( ParentPop, ParentPop, Channel1, Channel2, Color, Name ) 
    return region 
 
def CreateEllipseGate( TestPop, ParentPop, Channel1, Channel2, Color, Name="" ): 
 
    __test = basisGating.py22DStatsSample( TestPop.name(), Channel1, Channel2 ) 
 
    if __test.isOK(): 
        coordinates = __test.ellipse(2) 
        region = standardGating.applyEllipticGate( ParentPop, coordinates, Channel1, Channel2, 
Color ) 
        if Name != "": 
            region.setName( Name ) 
        return region 
 
    return None 
 
#------------------------------------------------------- 
# ScripText Bausteine 
#------------------------------------------------------- 
def getStatisticScriptText( pop, topName, func, channel='FSC' ): 
    #mDebug( 'log', 0, 'getStatsticScriptText:', topName, pop, func, channel ) 
    pop_desc = em_utilities.getPopScriptText( topName, pop ) 
    script_text_part = '%s.statistic("%s").%s()' % ( pop_desc, channel, func ) 
    return script_text_part 
 
def makeScriptTextPart( part, precision ): 
    if precision != '': 
        precision = "%" + precision + " % " 
    script_text = '$$' + precision + part + '$$' 
    return script_text 
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def createTableHeader( title, columns, version=False): 
    title_text = "<table cellspacing='-1' cellpadding='0'>" 
    title_text +=  "<tr align='left'>" 
    title_text +=    "<th><h3><u>%s</u></h3></th>" % title 
    for i in xrange( 2, columns ): 
        title_text +=    "<th></th>" 
    if version: 
        title_text +=    "<td align='right'>%s</td>" % version 
    else: 
        title_text +=    "<th></th>" 
    title_text +=  "</tr>" 
 
    title_text += em_utilities.html_emptyLine( columns ) 
 
    return title_text 
 
def getMedianScriptTextParts( fraction, sampleName, channels_A ): 
    median = { 
        "Donor"    : getStatisticScriptText( fraction['Donor'].name(),    sampleName, 'median', 
channels_A['VioBlue'] ), 
        "Acceptor" : getStatisticScriptText( fraction['Acceptor'].name(), sampleName, 'median', 
channels_A['FITC'] ), 
        "FRET"     : getStatisticScriptText( fraction['FRET'].name(),     sampleName, 'median', 
channels_A['VioGreen'] ) 
    } 
    return median 
 
def getIntensityScriptTexts( fraction, blank_fraction, sampleName, channels_A ): 
    medians = getMedianScriptTextParts( fraction, sampleName, channels_A ) 
    median_blank = getMedianScriptTextParts( blank_fraction, sampleName, channels_A ) 
    intensity = {} 
    for elm in ('Donor', 'Acceptor', 'FRET'): 
        intensity[elm] = medians[elm] + '-' + median_blank[elm]   
    return intensity 
     
def getIntensityScriptTextsFRET( fraction, sampleName, channels_A ): 
    medians = getMedianScriptTextParts( fraction, sampleName, channels_A ) 
    intensity = {}     
#-----------------------------------------------     
    file = open("FRETintensityFile.cal", "r") 
    contents = file.read() 
    print "FRET FILE:", contents 
    lastLine = contents.split("\n")[-2]     
    finalstring = lastLine.replace("}" , ""); 
    #Splitting the string based on , we get key value pairs 
    list = finalstring.split(",") 
    print "List is:", list 
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    ImportDict ={} 
    for elements in list: 
        print "elements:", elements 
        if ":" in elements: 
            #Get Key Value pairs separately to store in dictionary 
            keyvalue = elements.split(":")    
            #Replacing the single quotes in the leading. 
            m= keyvalue[0].strip('\'') 
            m = m.replace("\"", "") 
            ImportDict[m] = keyvalue[1].strip('"\'') 
     
    print ImportDict 
    file.close() 
             
    median_blank = { 
        'Donor' : ImportDict["VioBlue"], 
        'FRET': ImportDict["VioGreen"], 
        'Acceptor': ImportDict["FITC"]} 
    print "median_blank", median_blank 
  #-----------------------------------------------------        
    for elm in ('Donor', 'Acceptor', 'FRET'): 
        intensity[elm] = '(%s - %s)' %(medians[elm], median_blank[elm]) 
 
    return intensity 
     
 
def getCrossTalkScriptTexts( fractions, sampleName, channels_A ): 
 
    crossTalk = {} 
    Donor_Intensity = getIntensityScriptTexts( fractions['VioBlue_Donor'], fractions['Blank'], 
sampleName, channels_A ) 
    crossTalk['S3m'] = '( %s ) / ( %s )' %( Donor_Intensity['Acceptor'], 
Donor_Intensity['Donor'] ) 
    crossTalk['S1m'] = '( %s ) / ( %s )' %( Donor_Intensity['FRET'],     Donor_Intensity['Donor'] ) 
 
    Acceptor_Intensity = getIntensityScriptTexts( fractions['FITC_Acceptor'], fractions['Blank'], 
sampleName, channels_A ) 
    crossTalk['S2m'] = '( %s ) / ( %s )' %( Acceptor_Intensity['FRET'],  
Acceptor_Intensity['Acceptor'] ) 
    crossTalk['S4m'] = '( %s ) / ( %s )' %( Acceptor_Intensity['Donor'], 
Acceptor_Intensity['Acceptor'] ) 
 
    return crossTalk 
     
def getCrossTalkScriptTextsFRET( fractions, sampleName, channels_A ): 
     
    file = open("FRETintensityFile.cal", "r") 
    contents = file.read() 
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    lastLine = contents.split("\n")[-2]     
    finalstring = lastLine.replace("}" , ""); 
    #Splitting the string based on , we get key value pairs 
    list = finalstring.split(",") 
     
    ImportDict ={} 
    for elements in list: 
        print "elements:", elements 
        if ":" in elements: 
            keyvalue = elements.split(":")    
            #Get Key Value pairs separately to store in dictionary 
            #Replacing the single quotes in the leading. 
            m= keyvalue[0].strip('\'') 
            m = m.replace("\"", "") 
            ImportDict[m] = keyvalue[1].strip('"\'')     
    file.close()     
    # Crosstalk values 
    crossTalk = {} 
    crossTalk['S1m'] = float(ImportDict['S1m']) 
    crossTalk['S2m'] = float(ImportDict['S2m']) 
     
    return crossTalk 
 
def getFinalScriptTexts( scripttext_dict, precision, extension=False ): 
    for key,value in scripttext_dict.items(): 
        if extension: 
            scripttext_dict[key] = "<#$$setvar( '%s', %s )$$>" % ( key, value ) 
            scripttext_dict[key] += "<#$$sample.createExtension('FRET').storeValue( '%s', 
var['%s'] )$$>" %( key, key ) 
            scripttext_dict[key] += makeScriptTextPart( "var['%s']" %( key ), '.3f' ) 
        else: 
            scripttext_dict[key] = makeScriptTextPart( value, precision ) 
 
    return scripttext_dict 
     
 
def table_row( values ): 
    """Return a table row""" 
    line = "<tr align='left'>" 
    for i, elm in enumerate(values) : 
        if i<len(values)-1: 
            line += "<td>%s</td>" % elm 
        else: 
            line += "<td align='right'>%s</td>" % elm 
    line += "</tr>" 
    return line 
 
#------------------------------------------------------- 
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# ScripText Tabellen 
#------------------------------------------------------- 
def createIntensitiesTable( sampleName, fractions, channels_A ): 
 
    resultTab = createTableHeader( "Intensities (Median)", 4, version=em_version ) 
    resultTab += "<tr align='left'>" \ 
                 "<th> Sample</th>" \ 
                 "<th>Donor</th>" \ 
                 "<th>Acceptor</th>" \ 
                 "<th align='right'>FRET</th>" \ 
                 "</tr>" 
    resultTab += em_utilities.html_line( 4 ) 
 
    table_list = { 
        "Unlabeled"     : getFinalScriptTexts( getMedianScriptTextParts( fractions['Blank'],         
sampleName, channels_A ), '.3f', extension=True ), 
        "Donor only"    : 
getFinalScriptTexts( getMedianScriptTextParts( fractions['VioBlue_Donor'], sampleName, 
channels_A ), '.3f' ), 
        "Acceptor only" : 
getFinalScriptTexts( getMedianScriptTextParts( fractions['FITC_Acceptor'], sampleName, 
channels_A ), '.3f' ), 
        "FRET"          : 
getFinalScriptTexts( getMedianScriptTextParts( fractions['VioGreen_FRET'], sampleName, 
channels_A ), '.3f' ) 
    } 
 
    for name in ('Unlabeled', 'Donor only', 'Acceptor only', 'FRET'): 
        entry = table_list[name] 
        resultTab += table_row( ( name, entry['Donor'], entry['Acceptor'], entry['FRET'] ) ) 
 
    resultTab += "</table>" 
 
    return resultTab 
     
def createIntensitiesTableFRET( sampleName, fractions, channels_A ): 
 
    resultTab = createTableHeader( "Intensities (Median)", 4, version=em_version ) 
    resultTab += "<tr align='left'>" \ 
                 "<th> Sample</th>" \ 
                 "<th>Donor</th>" \ 
                 "<th>Acceptor</th>" \ 
                 "<th align='right'>FRET</th>" \ 
                 "</tr>" 
    resultTab += em_utilities.html_line( 4 ) 
 
    table_list = { 
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        "FRET"          : 
getFinalScriptTexts( getMedianScriptTextParts( fractions['VioGreen_FRET'], sampleName, 
channels_A ), '.3f' ) 
    } 
 
    entry = table_list['FRET'] 
    resultTab += table_row( ( 'FRET', entry['Donor'], entry['Acceptor'], entry['FRET'] ) ) 
    resultTab += "</table>" 
    return resultTab 
 
def createBackGroundTable( sampleName, fractions, channels_A ): 
 
    columns = 4 
    resultTab = createTableHeader( "Background subtraction", columns ) 
    resultTab += "<tr align='left'>" \ 
                 "<th> Sample</th>" \ 
                 "<th>Donor</th>" \ 
                 "<th>Acceptor</th>" \ 
                 "<th align='right'>FRET</th>" \ 
                 "</tr>" 
    resultTab += em_utilities.html_line( columns ) 
 
    table_list = { 
        "Donor only"    : getFinalScriptTexts( getIntensityScriptTexts( fractions['VioBlue_Donor'], 
fractions['Blank'], sampleName, channels_A ), '.3f' ), 
        "Acceptor only" : getFinalScriptTexts( getIntensityScriptTexts( fractions['FITC_Acceptor'], 
fractions['Blank'], sampleName, channels_A ), '.3f' ), 
        "FRET"          : getFinalScriptTexts( getIntensityScriptTexts( fractions['VioGreen_FRET'], 
fractions['Blank'], sampleName, channels_A ), '.3f' ), 
    } 
 
    for name in ('Donor only', 'Acceptor only', 'FRET'): 
        entry = table_list[name] 
        resultTab += table_row( ( name, entry['Donor'], entry['Acceptor'], entry['FRET'] ) ) 
 
    resultTab += '</table>' 
 
    return resultTab 
 
def createResultsTableFRET( sampleName, fractions, alphaFactor, channels_A ): 
     
    FRET_Intensity = getIntensityScriptTextsFRET( fractions['VioGreen_FRET'], sampleName, 
channels_A ) 
    crossTalk      = getCrossTalkScriptTextsFRET( fractions, sampleName, channels_A ) 
 
    stepFRET = '( %s - ( %s )*( %s ) - ( %s )*( %s ) ) / ( %s )' %( 
        FRET_Intensity['FRET'], FRET_Intensity['Donor'], crossTalk['S1m'], 
        FRET_Intensity['Acceptor'], crossTalk['S2m'], FRET_Intensity['Donor'] 
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    ) 
 
    A_FRET = '( %s ) / %f ' %( stepFRET, alphaFactor) 
    FRETe = '( %s ) / ( 1 + %s )' %( A_FRET, A_FRET )      
    FRETe = makeScriptTextPart( FRETe, '.3f' )     
    columns = 2 
    resultTab = createTableHeader( "Results", columns ) 
    resultTab += "<tr align='left'>" \ 
                 "<th></th>" \ 
                 "<th align='right'>Value</th></tr>" 
    resultTab += em_utilities.html_line( columns ) 
 
    alphaFactor = '%.3f' % alphaFactor 
    resultTab += table_row( ('alpha factor', alphaFactor) ) 
    resultTab += em_utilities.html_emptyLine( columns ) 
    resultTab += table_row( ("FRET efficiency median", FRETe ) ) 
    resultTab += "</table>" 
 
    return resultTab 
     
def createExportFRET( sampleName, fractions, alphaFactor, channels_A ):      
         
    #-----------------------------------------------     
    file = open("FRETintensityFile.cal", "r") 
    contents = file.read()     
    lastLine = contents.split("\n")[-2]     
    finalstring = lastLine.replace("}" , ""); 
    #Splitting the string based on , we get key value pairs 
    list = finalstring.split(",") 
    ImportDict ={} 
    for elements in list: 
        print "elements:", elements 
        if ":" in elements: 
            keyvalue = elements.split(":")    
            m= keyvalue[0].strip('\'') 
            m = m.replace("\"", "") 
            ImportDict[m] = keyvalue[1].strip('"\'')     
    print ImportDict 
    file.close() 
             
    median_blankExp = { 
        'Donor' : float(ImportDict["VioBlue"]), 
        'FRET': float(ImportDict["VioGreen"]), 
        'Acceptor': float(ImportDict["FITC"])} 
 
  #-----------------------------------------------------    
    mediansExp = {} 
    mediansExp['Donor'] = fractions['VioGreen_FRET']['Donor'].statistic("V1-A").median() 
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    mediansExp['Acceptor'] = fractions['VioGreen_FRET']['Acceptor'].statistic("B1-A").median() 
    mediansExp['FRET'] = fractions['VioGreen_FRET']['FRET'].statistic("V2-A").median() 
    intensityExp = {}          
    for elm in ('Donor', 'Acceptor', 'FRET'): 
        intensityExp[elm] = (mediansExp[elm] - median_blankExp[elm]) 
         
    #------------------------------------------------------- 
    crossTalk      = getCrossTalkScriptTextsFRET( fractions, sampleName, channels_A ) 
     
    stepFRETExp = (intensityExp['FRET'] - intensityExp['Donor'] * crossTalk['S1m'] - 
        intensityExp['Acceptor']* crossTalk['S2m'])/ intensityExp['Donor']         
     
    A_FRETExp = stepFRETExp/ float(alphaFactor) 
    FRETeExp =  A_FRETExp/( 1+ A_FRETExp )  
    print 'FRET for export:', FRETeExp 
    FRETe = "%.3f" % FRETeExp 
     
    Sample = App.sample( sampleName ) 
    Extension = Sample.createExtension("FRET")     
    Extension.storeValue("FRETe", FRETe ) 
    return u' ' 
     
def createCrosstalkTable( sampleName, fractions, channels_A ): 
 
    columns = 2 
    resultTab = createTableHeader( "Cross Talk", columns ) 
    resultTab += "<tr align='left'>" \ 
                 "<th></th>" \ 
                 "<th align='right'>Value</th>" \ 
                 "</tr>" 
    resultTab += em_utilities.html_line( columns ) 
 
    crossTalkParts = getCrossTalkScriptTexts( fractions, sampleName, channels_A ) 
    crossTalk = getFinalScriptTexts( crossTalkParts, '.3f', extension=True ) 
 
    for name in ('S1m', 'S3m', 'S2m', 'S4m'): 
        entry = crossTalk[name] 
        resultTab += table_row( ( name, entry ) ) 
 
    resultTab += "</table>" 
 
    return resultTab 
 
def createResultsTable( sampleName, fractions, alphaFactor, channels_A ): 
 
    FRET_Intensity = getIntensityScriptTexts( fractions['VioGreen_FRET'], fractions['Blank'], 
sampleName, channels_A ) 
    crossTalk      = getCrossTalkScriptTexts( fractions, sampleName, channels_A ) 
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    stepFRET = '( %s - ( %s )*( %s ) - ( %s )*( %s ) ) / ( %s )' %( 
        FRET_Intensity['FRET'], FRET_Intensity['Donor'], crossTalk['S1m'], 
        FRET_Intensity['Acceptor'], crossTalk['S2m'], FRET_Intensity['Donor'] 
    ) 
    A_FRET = '( %s ) / %f ' %( stepFRET, alphaFactor) 
    FRETe = '( %s ) / ( 1 + %s )' %( A_FRET, A_FRET ) 
    FRETe = makeScriptTextPart( FRETe, '.3f' ) 
     
    #TODO: write FRETe in extension 
    Sample = App.sample( sampleName ) 
    Extension = Sample.createExtension("FRET") 
    Extension.storeValue("FRETe", FRETe ) 
 
    columns = 2 
    resultTab = createTableHeader( "Results", columns ) 
    resultTab += "<tr align='left'>" \ 
                 "<th></th>" \ 
                 "<th align='right'>Value</th></tr>" 
    resultTab += em_utilities.html_line( columns ) 
 
    alphaFactor = '%.3f' % alphaFactor 
    resultTab += table_row( ('alpha factor', alphaFactor) ) 
    resultTab += em_utilities.html_emptyLine( columns ) 
    resultTab += table_row( ("FRET efficiency median", FRETe ) ) 
 
    resultTab += "</table>" 
 
    return resultTab 
 
def createMedianTable( sampleName, fraction, channels_A ): 
 
    columns = 2 
    resultTab = createTableHeader( "Median Intensities", columns ) 
    resultTab += "<tr align='left'>" \ 
                 "<th>Population</th>" \ 
                 "<th align='right'>Median</th>" \ 
                 "</tr>" 
    resultTab += em_utilities.html_line( columns ) 
 
    medians = getFinalScriptTexts( getMedianScriptTextParts( fraction, sampleName, 
channels_A ), '.3f' ) 
 
    for entry in ('Donor', 'Acceptor', 'FRET'): 
        resultTab += table_row( (entry,    medians[entry]) ) 
 
    resultTab += "</table>" 
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    return resultTab 
 
###########################################################################
############################ 
#------------------------------------------------------- 
# Main interface to analyse data from app 
#------------------------------------------------------- 
def viewPage( SampleName ): 
    analyseSample( SampleName ) 
 
def analyseSample( SampleName ): 
    def createPage( SampleName, PageType, alpha, __Fractions, FractionName=None ): 
        PageManager = basisEasyPageManager.singleton( ) 
        Page = PageManager.appendPage( PageType, ( SampleName, alpha, __Fractions, 
FractionName ) ) 
        Page.showPage( ) 
 
    mDebug( 'log', 0, 'analyse ...' ) 
 
    pv = em_utilities.cfgProgView('Analyzing data...','FRET_MultiSample', 8) 
 
    # Create Gating 
    try: 
        success, Fractions = __analyseFRET( SampleName, pv ) 
        mDebug( 'log', 0, "Done Analysis:", success ) 
 
    except em_utilities.AnalysisException, e: 
        mDebug( 'log', 0, "Error while analyzing %s %s ..." %( SampleName, e.message ) ) 
        mDebug( 'log', 0, str(e.message) ) 
        import traceback 
        traceback.print_exc() 
        Fractions = e.createdGates 
        success = False 
 
    except Exception, e: 
        mDebug( 'log', 0, 'Error while analyzing %s %s ...'%( SampleName, e ) ) 
        mDebug( 'log', 0, str(e) ) 
        import traceback 
        traceback.print_exc() 
        success = False 
        Fractions = {} 
 
    if success == False: 
 
        em_utilities.hideProgView( ) 
        Script.critical("FRET analysis error", "Failed to analyse data %s ..." %( SampleName ) ) 
 
    else: 
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        try: 
 
            Sample = App.sample( SampleName ) 
            channels_A = em_utilities.get_channelNames( "A", channel_list, Sample ) 
            channels_H = em_utilities.get_channelNames( "H", channel_list, Sample ) 
 
            # Get alpha 
            # Create Pages 
            # keylist: List with predefined order containing all possible Fractions 
            keylist = [ 'Blank', 'VioBlue_Donor', 'FITC_Acceptor', 'VioGreen_FRET' ] 
            for key in keylist: 
                if key not in Fractions.keys(): keylist.remove( key ) 
            # mDebug( 'log', 0, 'sortierte Liste der gemessenen Fraktionen', keylist ) 
             
            if 'Blank' in keylist: 
                 
                print'BLANK is in fraction, running controls' 
                 
                alpha = getAlphaFromDescription( Sample ) 
                mDebug( 'log', 0, "Found alpha:", alpha ) 
 
                for fractionName in keylist: 
                    createPage( SampleName, FRETAnalysePage1, alpha, Fractions, fractionName ) 
                     
                createPage( SampleName, FRETAnalysePage2, alpha, Fractions ) 
                createPage( SampleName, FRETAnalysePage3, alpha, Fractions ) 
     
                pv.setProgress( 6 ) 
     
                # Create new mqd file with FRET-Channel 
                Extension = Sample.createExtension("FRET") 
                Extension.storeValue("alpha factor", alpha ) 
                # Extension.storeValue("Fractions", str(Fractions)) 
                FretSample = CreateFretEfficiencySampleFile( SampleName, Fractions, channels_A, 
channels_H ) 
                pv.setProgress( 7 ) 
     
                Fractions = __analyseFRET2( FretSample, pv, Fractions ) 
                createPage( FretSample, FRETAnalysePage4, alpha, Fractions, 'FRET' ) 
                 
            else: 
                print 'FRET Sample only' 
                 
                alpha = getAlphaFromCSV( Sample ) 
                mDebug( 'log', 0, "Found alpha:", alpha )                 
                createPage( SampleName, FRETAnalysePageFRETonly, alpha, Fractions ) 
                pv.setProgress( 6 ) 
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            em_utilities.hideProgView( ) 
 
        except Exception, e: 
            em_utilities.hideProgView() 
            mDebug( 'log', 0, e ) 
            import traceback 
            traceback.print_exc() 
             
             
def analyseSamplePS( SampleName): 
    #variabels = ["SampleID", "Param1", "Param2", "Param3"] 
    # wenn nur eine variable: 
    variabels = ["FRET Efficiency", "Calib-Date"] 
    sample = App.sample( SampleName ) 
    Ext = sample.createExtension("FRET") 
    FRETe = Ext.getValue("FRETe") 
     
    file = open("FRETintensityFile.cal", "r") 
    contents = file.read() 
    print "FRET FILE:", contents 
    lastLine = contents.split("\n")[-2]     
    finalstring = lastLine.replace("}" , ""); 
    #Splitting the string based on , we get key value pairs 
    list = finalstring.split(",") 
    print "List is:", list 
     
    ImportDict ={} 
    for elements in list: 
        print "elements:", elements 
        if ":" in elements: 
            #Get Key Value pairs separately to store in dictionary 
            keyvalue = elements.split(":", 1)    
            #Replacing the single quotes in the leading. 
            m= keyvalue[0].strip('\'') 
            m = m.replace("\"", "") 
            ImportDict[m] = keyvalue[1].strip('"\'')     
    file.close() 
    CalibTime = ImportDict['time'] 
    #FRETe = 12 
     
    values = [FRETe, CalibTime ] 
    status = True 
 
    return status, variabels, values 
 
 
#------------------------------------------------------- 
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# Functions for FRET-Calculation 
#------------------------------------------------------- 
def getAlphaFromDescription( sample ): 
    description = sample.description( sample.DescriptionPatient ) 
 
    alpha = 0.2  # default value for alpha 
    # this will be used, in case it cannot be determined from the description 
 
    description = description.replace( ",", "." ) 
    try: 
        alpha = float( description ) 
    except: 
        re_pattern = '(?i)alpha *=* *([0-9]+[.,]?[0-9]*)' 
        m = re.search( re_pattern, description ) 
        if m: 
            alpha = float( m.group( 1 ) ) 
    return alpha 
     
def getAlphaFromCSV( sample ): 
 
    alpha = 0.3533  # default value for alpha 
     
    file = open("FRETintensityFile.cal", "r") 
    contents = file.read() 
    print "FRET FILE:", contents 
    lastLine = contents.split("\n")[-2]     
    finalstring = lastLine.replace("}" , ""); 
    #Splitting the string based on , we get key value pairs 
    list = finalstring.split(",") 
    print "List is:", list 
     
    ImportDict ={} 
    for elements in list: 
        print "elements:", elements 
        if ":" in elements: 
            #Get Key Value pairs separately to store in dictionary 
            keyvalue = elements.split(":")    
            #Replacing the single quotes in the leading. 
            m= keyvalue[0].strip('\'') 
            m = m.replace("\"", "") 
            ImportDict[m] = keyvalue[1].strip('"\'')     
    file.close() 
    alpha = float(ImportDict['alphaFactor']) 
    return alpha 
 
def CreateFretEfficiencySampleFile( SampleName, Fractions, channels_A, channels_H ): 
 
    # Check, if to be created file is already loaded 
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    # unload first, to avoid problems at overwriting it 
    NewSampleName = SampleName + 'FRET' 
    sample = App.sample( NewSampleName ) 
    if sample: 
        if App.isAnalysisMode(): 
            App.setAnalysisMode( False ) 
        App.removeSample( sample ) 
 
    sample = App.sample(SampleName) 
    sampleFileName = sample.filename() 
    dataDir = os.path.dirname( sampleFileName ) 
    FRET_FileName = dataDir + '\\' + NewSampleName + '.mqd' 
 
    #START calculate new FRET file by cell analysis file 
 
    # Get stored values from Extension of analyzed file 
    Ext = sample.createExtension("FRET") 
 
    # Background Values in all FRET channels 
    BG = { 
        'VioBlue' : Ext.getValue("Donor"), 
        'VioGreen': Ext.getValue("FRET"), 
        'FITC': Ext.getValue("Acceptor") 
    } 
    # Crosstalk values 
    S1m         = Ext.getValue("S1m") 
    S2m         = Ext.getValue("S2m") 
     
    #TODO: maybe write CSV here with all data 
    #test in print 
    #possibly easier than single values 
    print 'BG values---:', BG     
     
    alphaFactor = Ext.getValue("alpha factor") 
    file = open("FRETintensityFile.cal","a") 
    #sep = ";" 
    sep = "," 
    file.write("'time':"+str(time.ctime())+sep) 
     
    myList = [] 
    myList2 = [] 
    myList.append(BG) 
    valueDict = {} 
    valueDict["S1m"] = S1m 
    valueDict["S2m"] = S2m 
    valueDict["alphaFactor"] = alphaFactor 
    myList2.append(valueDict) 
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    for entry in myList: 
        myLine = "" 
        for key,value in entry.items(): 
            myLine += ("'"+ key + "':") 
            myLine += (str(value)+sep) 
    file.write(myLine) 
     
    for entry2 in myList2: 
        myLine2 = "" 
        for key,value in entry2.items(): 
           # myLine2 += (key + sep) 
            #myLine2 += (str(value)+sep) 
            myLine2 += ("'"+ key + "':") 
            myLine2 += (str(value)+sep) 
    file.write(myLine2) 
    file.write("\n") 
    file.close() 
     
 
    # Set New Features for FRET_Analyse 
    Features = mq.Features(0) 
 
    Features.appendFeature( SetFeature( "FRET-Efficiency", "FRET",        "FRET-Efficiency",  
150.0, 0.0,   100.0, mq.Feature.Linear, mq.Feature.Linear) ) 
    Features.appendFeature( SetFeature( "FSC-A",           "FSC-A",       "FSC-A",           1000.0, 
0.0,  1000.0, mq.Feature.Linear, mq.Feature.Linear) ) 
    Features.appendFeature( SetFeature( "SSC-A",           "SSC-A",       "SSC-A",           1000.0, 
0.0,  1000.0, mq.Feature.Linear, mq.Feature.Linear) ) 
    Features.appendFeature( SetFeature( "FSC-H",           "FSC-H",       "FSC-H",           1000.0, 
0.0,  1000.0, mq.Feature.Linear, mq.Feature.Linear) ) 
    Features.appendFeature( SetFeature( "VioBlue-A",       "Donor",       "VioBlue-A",       
1000.0, 0.01, 1000.0, mq.Feature.Linear, mq.Feature.Logarithmic ) ) 
    Features.appendFeature( SetFeature( "FITC-A",          "Acceptor",    "FITC-A",          1000.0, 
0.01, 1000.0, mq.Feature.Linear, mq.Feature.Logarithmic ) ) 
    Features.appendFeature( SetFeature( "VioGreen-A",      "FRETchannel", "VioGreen-A",      
1000.0, 0.01, 1000.0, mq.Feature.Linear, mq.Feature.Logarithmic ) ) 
 
    FRET_fraction = Fractions['VioGreen_FRET']['GroupGateName'] 
    group_count = FRET_fraction.eventCount() 
 
    # create new mqdFile with additional channels for FRET calculations 
    FRET_File = mq.MqdWriter() 
    if not FRET_File.create( FRET_FileName, Features, group_count ): 
        raise Exception( "Failed to create destination file" ) 
 
    # get old mqdFileInfo, in order to retrieve meta info to store to new file 
    filename = sample.filename() 
    OldFileInfo = mq.MqdFileInfo( filename ) 
Appendix 
 
117 
 
 
    channelLookup = createChannelLookup( OldFileInfo ) 
 
    for event_index in xrange( group_count ): 
        event = CalcFretEfficiency( event_index, channelLookup, BG, S1m, S2m, alphaFactor, 
FRET_fraction, channels_A, channels_H ) 
        FRET_File.append( event ) 
 
    # retrieve remaining stuff from old file and finalize it 
    FRET_File.setDeviceSettings( OldFileInfo.deviceSettings() ) 
    FRET_File.setViewPage( OldFileInfo.viewPage() ) 
    FRET_File.setExtension( OldFileInfo.extension() ) 
    FRET_File.finalize() 
 
    if not App.load( FRET_FileName ): 
        raise Exception( "Failed to load destination file" ) 
 
    return NewSampleName 
 
def CalcFretEfficiency( event_index, channelLookUp, BG, S1m, S2m, alphaFactor, 
FRET_fraction, channels_A, channels_H ): 
    # get Background corrected event-values for VioBlue, VioGreen and FITC parameter: 
    newValues = {} 
    for channelName in ( 'VioBlue', 'VioGreen', 'FITC' ): 
        LookUp = channelLookUp[ channels_A[ channelName ] ] 
        param_index = LookUp['index'] 
        old_value = FRET_fraction.value( event_index, param_index ) 
        newValues[ channelName ] = old_value * LookUp['scaleMax'] - BG[channelName] 
    #TDODO: write CSV with channel LookUp 
    # print values 
    #use param_index se in print results   
         
    #Calculation of FRET efficiency 
    stepFRET = ( newValues['VioGreen'] - newValues['VioBlue'] * S1m - newValues['FITC'] * 
S2m ) / newValues['VioBlue'] 
    A_FRET   = stepFRET / alphaFactor 
    fretEff  = A_FRET / ( 1 + A_FRET ) 
 
    # re-Normalize corrected Fluorescence-values 
    VioBlue  = newValues['VioBlue'] / channelLookUp[ channels_A['VioBlue'] ]['scaleMax'] 
    FITC     = newValues['FITC'] / channelLookUp[ channels_A['FITC'] ]['scaleMax'] 
    VioGreen = newValues['VioGreen'] / channelLookUp[ channels_A['VioGreen'] ]['scaleMax'] 
 
    # get event Index for Scatter Parameter: 
    # Index_SSC = channelLookUp[ channels['SSC'] ]['index'] 
    # Index_FSC = channelLookUp[ channels['FSC'] ]['index'] 
    for channelName in ( 'SSC', 'FSC' ): 
        LookUp = channelLookUp[ channels_A[channelName] ] 
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        newValues[ channelName ] = FRET_fraction.value( event_index, LookUp['index'] ) 
 
    LookUp = channelLookUp[ channels_H['FSC'] ] 
    newValues[ 'FSC-H' ] = FRET_fraction.value( event_index, LookUp['index'] ) 
 
    # return new event 
    return fretEff, newValues['FSC'], newValues['SSC'], newValues['FSC-H'], VioBlue, FITC, 
VioGreen 
 
def SetFeature( userDefName, name, param, maxRange, minScale, maxScale, RangeType, 
ScaleType ): 
    #mDebug( 'log', 0, "setFeature: ", userDefName ) 
    Feature = mq.Feature() 
    Feature.setUserdefName( userDefName ) 
    Feature.setBaseInfo( name, param, 0, 4) 
    Feature.setDataRange(0.0, maxRange, RangeType ) 
    Feature.setScale(minScale, maxScale, ScaleType ) 
    Feature.setFactor(1.0) 
    Feature.setGain(100) 
    return Feature 
 
def createChannelLookup( OldFile ): 
    eventsize = OldFile.features().count() 
    channelLookUp = {} 
    for i in xrange( 1, eventsize ): 
        feature = OldFile.features().feature( i ) 
        channelLookUp[ feature.name() ] = { 'index' : i, 'scaleMax' : feature.scaleMax() } 
    return channelLookUp 
 
#------------------------------------------------------- 
# Main interface to get a acquisition page 
#------------------------------------------------------- 
def getAcqPage( ): 
    PagetManager = basisEasyPageManager.singleton( ) 
    Page = PagetManager.appendPage( FRETAcquisitionPage ) 
    Page.showPage( ) 
 
def getAcqProcObject( ): 
    return FRETExpressProzessor( ) 
 
class FRETExpressProzessor( basisExpressMode.ExpressProzessor ): 
    def __init__( self ): 
        basisExpressMode.ExpressProzessor.__init__( self ) 
 
    def prolog( self ): 
        # get current IS 
        IS = mq.getCurrentInstrumentSettings() 
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        # copy and store for restoring after measurement 
        self.mCurInstSetting = mq.deepCopyInstrumentSetting( IS ) 
        # this is necessary, so that epilog can be done, even though prolog was not finished 
properly 
 
        # check for FL7 instrument; and stop here; EM Analysis needs VioGreen channel and 
thus 
        # is not compatible to FL7 instruments 
        if IS.profileName()[0] == "FL7": 
            self.setState( basisExpressMode.CSTATE.ERROR ) 
            message = "Expressmode " + em_name + " not compatible with your 
Instrument.<BR>" 
            message += "You need a MQ10 or VYB instrument to run this expressmode." 
            Script.showMessage( em_name, "<H3 align=center >"+message+"</H3>", 
( "Abort", ) ) 
            return 
 
        # set fluorescence channels to 'log5' 
        for channel in IS.channels(): 
            if channel.isFluorescence(): 
                IS.channel( channel.name() ).setMode( 'log5' ) 
 
        IS.enableCompensation( False ) 
 
        # enable modified IS 
        mq.takeInstrumentSettingsAsCurrent( IS ) 
 
        basisExpressMode.ExpressProzessor.prolog( self ) 
 
    def epilog( self ): 
        # reset IS to settings as found in prolog 
        mq.takeInstrumentSettingsAsCurrent( self.mCurInstSetting ) 
        return basisExpressMode.ExpressProzessor.epilog( self ) 
 
 
###########################################################################
############################ 
#---------------------------------------- 
# Main call 
#---------------------------------------- 
def run( ): 
 
    FileName = Script.getOpenFileName( "", "Open FRET_MultiSample-file for analysis", 
"*.mqd", "*.mqd" ) 
    if FileName != "" and FileName != None: 
        em_utilities.loadFCSFile( FileName ) 
        Temp = FileName.strip(".mqd").split("/") 
        Sample = Temp[-1] 
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        analyseSample( Sample ) 
         
    # for sn in samples... 
 
def pause( ): 
    pass 
 
def stop( ): 
    pass 
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9.2   The FRET Express Mode Post Paser Script 
 
import os 
import time 
from expressModes import basisEasyPage 
from expressModes import basisGating 
from expressModes import basisEasyPageTemplate 
from expressModes import basisEasyPageManager 
from expressModes.app.mq.express.Analysis import FRETexportData_testloops 
import utilities 
import basisCalibration 
import mq 
from profiles import hardware as hardwareProfiles 
 
from __main__ import App 
from __main__ import Script 
from __main__ import Config 
 
 
def run(): 
    print "Test" 
 
    inputPath = 
"C:/Users/kerstinv/Desktop/BerlinToAnalyze/P161202A1P4013/P161202A1P4013_" 
    files = [] 
    date = "_2016-12-05.0001.mqd" 
    letterlist = ["A", "B", "C", "D", "E", "F", "G", "H", "I", "J", "K", "L", "M", "N", "O", "P"] 
    letterlistControls = ["E", "F"] 
#    for i in xrange(3,19,1): #Files from 1 to 6 
#        number =str(i) 
#        #print number 
#        longNumber = "" 
#        for j in xrange(4-len(number)): 
#            longNumber += "0" 
#        longNumber +=number 
#        #print longNumber 
#        file = inputPath+longNumber+".mqd" 
#        files.append(file) 
#        print 'File:', file 
         
    for x in letterlist: 
        for y in xrange (21,23): 
            number =str(y) 
 
#            newNumber = number      
            print x, number 
            file = inputPath + x + number + date 
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            files.append(file) 
            print 'File:', file 
 
 
    #print files 
 
    header = "Results from analysis using EM 'FRET'\n\n" 
    header += "SampleName\tSampleID\tDescription\tStartTime\tEventCount\tStatus" 
 
    lines = "" 
 
    firstSample = True 
 
    for sample in files: 
 
        sampleName = sample.split("/")[-1][0:-4] 
        print "post processing of:", sampleName 
 
        # Apply express-mode to sample 
        Sample = App.sample( sampleName ) 
        ExpInfo = Sample.experiment() 
        if ExpInfo == None: 
            ExpInfo = "None" 
        print "Exp Info:", ExpInfo 
        FileInfo = mq.MqdFileInfo( Sample.filename() ) 
        features = FileInfo.features() 
 
        StartTime            = GetStartTimeText( features ) 
        DescriptionOfSample  = mq.ISampleExperimentInfo.description( ExpInfo )[0] 
        SampleID             = ''.join(mq.ISampleExperimentInfo.sampleId( ExpInfo )[0]) 
        EventCount           = str(Sample.eventCount()) 
 
        FRETexportData_testloops.analyseSample(sampleName) 
        status, variables, values = FRETexportData_testloops.analyseSamplePS(sampleName) 
 
        if firstSample: 
            # Open output-file 
            outputPath = "C:/Users/kerstinv/Desktop/ExportFiles_" 
            fullPath = outputPath + sampleName + "_FRET" + ".csv" 
            file = open(fullPath, "w") 
 
            # Complete header 
            for variable in variables: 
                header += "\t" + str(variable) 
            header += "\n" 
 
            firstSample = False 
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        # Create single line 
        line = sampleName 
        line += "\t" + SampleID 
        line += "\t" + DescriptionOfSample 
        line += "\t" + StartTime 
        line += "\t" + EventCount 
 
        line += "\t" + str(status) 
        for value in values: 
            line += "\t" + str(value) 
        line += "\n" 
 
        # Transfer single line to all lines 
        lines += line 
        print lines 
 
    file.write(header) 
    file.write(lines) 
    file.close() 
    print 'file is written' 
 
 
 
def GetStartTimeText( features ): 
    return features.startDate() + " " + features.startTime() 
 
 
 
